AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaHealth Care
Administration, IntravesicalUrinary Bladder NeoplasmsUrinary BladderBCG VaccineCarcinoma, Transitional CellCystitisCystoscopyUrinary Bladder DiseasesCystitis, InterstitialUrinationAdministration, OralPropanthelineUrinary Bladder, NeurogenicMitomycinUrodynamicsMandelic AcidsUreterUrinary Bladder, OveractiveCystotomyUrotheliumCystectomyMycobacterium bovisTuberculosis, CardiovascularUrinary Bladder Neck ObstructionNeoplasm Recurrence, LocalDose-Response Relationship, DrugDrug Administration ScheduleRats, Sprague-DawleyUreteral NeoplasmsImmunotherapyAntibiotics, AntineoplasticTuberculosis, Male GenitalReflex, AbnormalTime FactorsCarcinoma in SituDisease Models, AnimalUrethraTreatment OutcomeUrologic Surgical ProceduresAdjuvants, ImmunologicProstatismInjections, IntravenousAntineoplastic AgentsUnited States Food and Drug AdministrationUrination DisordersReflexRats, WistarNeuromuscular AgentsDrug Administration RoutesHyperthermia, InducedBotulinum Toxins, Type AMice, Inbred C57BLPentosan Sulfuric PolyesterHypogastric PlexusAcroleinUrinary CatheterizationUrologic NeoplasmsAneurysm, InfectedDogsAntimetabolites, AntineoplasticParasympatholyticsUrineAdministration, IntranasalCapsaicinMitomycinsNeurons, EfferentPressureDeoxycytidineUrinary Bladder CalculiNeurons, AfferentMucous MembraneCombined Modality TherapyUrinary TractInjections, IntraperitonealVesico-Ureteral RefluxMice, Inbred C3HMuscle ContractionKidney PelvisPelvisRats, Inbred F344Muscarinic Antagonists
Administration, Intravesical
The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.
Urinary Bladder
A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION.
BCG Vaccine
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
Carcinoma, Transitional Cell
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
Cystitis
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.
Cystoscopy
Endoscopic examination, therapy or surgery of the urinary bladder.
Urinary Bladder Diseases
Pathological processes of the URINARY BLADDER.
Cystitis, Interstitial
A condition with recurring discomfort or pain in the URINARY BLADDER and the surrounding pelvic region without an identifiable disease. Severity of pain in interstitial cystitis varies greatly and often is accompanied by increased urination frequency and urgency.
Urination
Discharge of URINE, liquid waste processed by the KIDNEY, from the body.
Administration, Oral
The giving of drugs, chemicals, or other substances by mouth.
Propantheline
A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.
Urinary Bladder, Neurogenic
Dysfunction of the URINARY BLADDER due to disease of the central or peripheral nervous system pathways involved in the control of URINATION. This is often associated with SPINAL CORD DISEASES, but may also be caused by BRAIN DISEASES or PERIPHERAL NERVE DISEASES.
Mitomycin
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
Urodynamics
The mechanical laws of fluid dynamics as they apply to urine transport.
Mandelic Acids
Analogs or derivatives of mandelic acid (alpha-hydroxybenzeneacetic acid).
Ureter
One of a pair of thick-walled tubes that transports urine from the KIDNEY PELVIS to the URINARY BLADDER.
Urinary Bladder, Overactive
Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.
Cystotomy
Surgical incision or puncture into a URINARY BLADDER. Cystotomy may be used to remove URINARY CALCULI, or to perform tissue repair and reconstruction.
Urothelium
The epithelial lining of the URINARY TRACT.
Cystectomy
Used for excision of the urinary bladder.
Mycobacterium bovis
The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis.
Tuberculosis, Cardiovascular
Pathological conditions of the CARDIOVASCULAR SYSTEM caused by infection of MYCOBACTERIUM TUBERCULOSIS. Tuberculosis involvement may include the HEART; the BLOOD VESSELS; or the PERICARDIUM.
Urinary Bladder Neck Obstruction
Blocked urine flow through the bladder neck, the narrow internal urethral opening at the base of the URINARY BLADDER. Narrowing or strictures of the URETHRA can be congenital or acquired. It is often observed in males with enlarged PROSTATE glands.
Neoplasm Recurrence, Local
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Dose-Response Relationship, Drug
The relationship between the dose of an administered drug and the response of the organism to the drug.
Drug Administration Schedule
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Rats, Sprague-Dawley
A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.
Ureteral Neoplasms
Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.
Immunotherapy
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Antibiotics, Antineoplastic
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Tuberculosis, Male Genital
MYCOBACTERIUM infections of the male reproductive tract (GENITALIA, MALE).
Reflex, Abnormal
An abnormal response to a stimulus applied to the sensory components of the nervous system. This may take the form of increased, decreased, or absent reflexes.
Time Factors
Elements of limited time intervals, contributing to particular results or situations.
Carcinoma in Situ
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
Disease Models, Animal
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Urethra
A tube that transports URINE from the URINARY BLADDER to the outside of the body in both the sexes. It also has a reproductive function in the male by providing a passage for SPERM.
Treatment Outcome
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Urologic Surgical Procedures
Surgery performed on the urinary tract or its parts in the male or female. For surgery of the male genitalia, UROLOGIC SURGICAL PROCEDURES, MALE is available.
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Prostatism
Lower urinary tract symptom, such as slow urinary stream, associated with PROSTATIC HYPERPLASIA in older men.
Injections, Intravenous
Injections made into a vein for therapeutic or experimental purposes.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS.
United States Food and Drug Administration
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
Urination Disorders
Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.
Reflex
An involuntary movement or exercise of function in a part, excited in response to a stimulus applied to the periphery and transmitted to the brain or spinal cord.
Rats, Wistar
A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.
Neuromuscular Agents
Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.
Drug Administration Routes
The various ways of administering a drug or other chemical to a site in a patient or animal from where the chemical is absorbed into the blood and delivered to the target tissue.
Hyperthermia, Induced
Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.
Botulinum Toxins, Type A
A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25.
Mice, Inbred C57BL
Pentosan Sulfuric Polyester
A sulfated pentosyl polysaccharide with heparin-like properties.
Hypogastric Plexus
A complex network of nerve fibers in the pelvic region. The hypogastric plexus distributes sympathetic fibers from the lumbar paravertebral ganglia and the aortic plexus, parasympathetic fibers from the pelvic nerve, and visceral afferents. The bilateral pelvic plexus is in its lateral extent.
Acrolein
Urinary Catheterization
Passage of a CATHETER into the URINARY BLADDER or kidney.
Urologic Neoplasms
Tumors or cancer of the URINARY TRACT in either the male or the female.
Aneurysm, Infected
Aneurysm due to growth of microorganisms in the arterial wall, or infection arising within preexisting arteriosclerotic aneurysms.
Dogs
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
Antimetabolites, Antineoplastic
Antimetabolites that are useful in cancer chemotherapy.
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS.
Urine
Liquid by-product of excretion produced in the kidneys, temporarily stored in the bladder until discharge through the URETHRA.
Administration, Intranasal
Delivery of medications through the nasal mucosa.
Capsaicin
An alkylamide found in CAPSICUM that acts at TRPV CATION CHANNELS.
Mitomycins
A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
Neurons, Efferent
Neurons which send impulses peripherally to activate muscles or secretory cells.
Pressure
A type of stress exerted uniformly in all directions. Its measure is the force exerted per unit area. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)
Deoxycytidine
Urinary Bladder Calculi
Stones in the URINARY BLADDER; also known as vesical calculi, bladder stones, or cystoliths.
Neurons, Afferent
Neurons which conduct NERVE IMPULSES to the CENTRAL NERVOUS SYSTEM.
Mucous Membrane
An EPITHELIUM with MUCUS-secreting cells, such as GOBLET CELLS. It forms the lining of many body cavities, such as the DIGESTIVE TRACT, the RESPIRATORY TRACT, and the reproductive tract. Mucosa, rich in blood and lymph vessels, comprises an inner epithelium, a middle layer (lamina propria) of loose CONNECTIVE TISSUE, and an outer layer (muscularis mucosae) of SMOOTH MUSCLE CELLS that separates the mucosa from submucosa.
Combined Modality Therapy
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Urinary Tract
The duct which coveys URINE from the pelvis of the KIDNEY through the URETERS, BLADDER, and URETHRA.
Injections, Intraperitoneal
Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall.
Vesico-Ureteral Reflux
Retrograde flow of urine from the URINARY BLADDER into the URETER. This is often due to incompetence of the vesicoureteral valve leading to ascending bacterial infection into the KIDNEY.
Mice, Inbred C3H
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.
Kidney Pelvis
The flattened, funnel-shaped expansion connecting the URETER to the KIDNEY CALICES.
Pelvis
The space or compartment surrounded by the pelvic girdle (bony pelvis). It is subdivided into the greater pelvis and LESSER PELVIS. The pelvic girdle is formed by the PELVIC BONES and SACRUM.
Rats, Inbred F344
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.

The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients. (1/242)

We investigated the potential existence of differences in the distribution of T-lymphocyte subsets and in the proliferative response of these CD2+ cells to polyclonal mitogens in patients with transitional cell bladder carcinoma (SBTCC) treated with prophylactic intracavitary instillations of bacillus Calmette-Guerin (BCG) according to their clinical response to this treatment. Before BCG treatment, different subset distribution (CD8+ and CD3+ CD56+), activation antigen expression (CD3+ HLA- DR+) and proliferative response to mitogenic signals were found in CD2+ cells from SBTCC patients prophylactically treated with BCG who remained free of disease or those who had recurrence of tumour. Otherwise, the prophylactic intracavitary BCG instillations in SBTCC patients are associated with a transitory variation of T-lymphocyte subset distribution (CD4 and CD8) and activation antigens expression (CD25).  (+info)

Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. (2/242)

We report a case of Mycobacterium bovis BCG vertebral osteomyelitis in a 79-year-old man 2.5 years after intravesical BCG therapy for bladder cancer. The recovered isolate resembled M. tuberculosis biochemically, but resistance to pyrazinamide (PZA) rendered that diagnosis suspect. High-pressure liquid chromatographic studies confirmed the diagnosis of M. bovis BCG infection. The patient was originally started on a four-drug antituberculous regimen of isoniazid, rifampin, ethambutol, and PZA. When susceptibility studies were reported, the regimen was changed to isoniazid and rifampin for 12 months. Subsequently, the patient was transferred to a skilled nursing facility for 3 months, where he underwent intensive physical therapy. Although extravesical adverse reactions are rare, clinicians and clinical microbiologists need to be aware of the possibility of disseminated infection by M. bovis BCG in the appropriate setting of clinical history, physical examination, and laboratory investigation.  (+info)

Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. (3/242)

More active and well-tolerated agents are needed for the treatment of superficial bladder cancer. This study investigated intravesical gemcitabine to establish the toxicology and pharmacokinetics necessary for clinical trials. Beagle dogs (in groups of 2; n = 6) received 100 mg, 350 mg, or 1 g of drug by intravesical administration on alternate days three times/week for 4 weeks. Animals were observed for clinical signs of toxicity; gemcitabine levels and peripheral blood counts were taken three times weekly. The dogs were euthanized, and a full necropsy was performed at days 1 and 14 after the last dose. Intravesical gemcitabine was given at 100 mg (n = 2), 350 mg (equivalent to the 1000 mg/m2 human dose; n = 3), and 3.5 g (n = 1). i.v. gemcitabine was given at 350 mg (n = 2). Plasma samples drawn at time points up to 8 h were analyzed for systemic absorption and clearance of drug. Doses of 100 and 350 mg were well tolerated with no clinical side effects. Necropsies revealed normal bone marrow cellularity and normal bladder histology. At 1 g, signs of severe clinical toxicity were evident, and after only three doses, necropsies demonstrated severe bone marrow hypoplasia, cystitis, and intestinal necrosis. At all intravesical doses, significant systemic absorption was seen. The T1/2 (+/- SD) for intravesical and i.v. administration of 350 mg was 328 (+/-6.8) min and 99.3 (+/-5.2) min, respectively (P<0.001). Intravesical gemcitabine is well tolerated and has no direct bladder toxicity at doses up to 1000 mg/m2. Higher doses result in gastrointestinal, bladder, and bone marrow toxicity.  (+info)

Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin. (4/242)

Although Mycobacterium bovis bacillus Calmette-Guerin (BCG) has been accepted as the most effective agent in clinical use against superficial bladder cancer, its mechanism of action remains incompletely understood. A kinetic analysis in assessing the potential role of cytokines from BCG-stimulated murine splenocytes showed that IL-12 expression preceded that of other cytokines. Experiments subtracting endogenous BCG-driven IL-12 using neutralizing Ab or augmenting its activity with supplemental rIL-12 revealed not only that IL-12 plays a dominant role in IFN-gamma induction but also that it is normally dose limiting. A striking increase in IFN-gamma production could be generated in both mouse and human immunocompetent cell culture by the addition of even a small amount of rIL-12. Moreover, this same synergistic effect could be replicated during in vivo administration of BCG plus rIL-12 into the mouse bladder and was observed in a patient receiving intravesical combination therapy. In costimulation cultures, this synergy appeared to partially rely on IL-18 and IL-2 and could be down-regulated by IL-10. This suggests that a dynamic interplay between Th1 and Th2 cytokines is responsible for net IFN-gamma production. The ability of supplemental exogenous IL-12 to strongly shift this balance toward Th1 provides an immunological basis for using it in conjunction with intravesical BCG for bladder cancer immunotherapy.  (+info)

Primary lymphoma of the bladder treated successfully with mitozantrone gel. (5/242)

We describe a young man who presented with a short history of painless haematuria. Subsequent investigations and biopsy of lesions found in his bladder at cystoscopy confirmed the diagnosis of primary lymphoma of the bladder. Computed tomography studies confirmed the disease was localised to his bladder. Unfortunately, the tumour was not eradicated by radiotherapy. However, it was successfully treated with intravesical mitozantrone given in a novel gel formation. Three years after diagnosis the patient remains well with no evidence of recurrence.  (+info)

Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. (6/242)

PURPOSE: More effective intravesical agents are required to limit the recurrence and progression of superficial bladder cancer. This study assessed the ability of copper-67 ((67)Cu)-C595 murine antimucin monoclonal antibody to bind selectively to superficial bladder tumors when administered intravesically, with a view to its development for therapy. PATIENTS AND METHODS: Approximately 20 MBq of (67)Cu-C595 monoclonal antibody was administered intravesically to 16 patients with a clinical indication of superficial bladder cancer. After 1 hour, the bladder was drained and irrigated. Tissue uptake was assessed by imaging and by the assay of tumor and normal tissues obtained by endoscopic resection. RESULTS: Tumor was correctly identified in the images of 12 of 15 patients who were subsequently found to have tumors. Assay of biopsy samples at 2 hours showed a mean tumor uptake of 59.4% of the injected dose per kilogram (SD = 48.0), with a tumor-to-normal tissue ratio of 14.6:1 (SD = 20). After 24 hours (n = 5), this decreased to 4.3% of the injected dose per kilogram (SD = 2.9), with a tumor-to-normal tissue ratio of 1.8:1 (SD = 0.8). CONCLUSION: This study indicates a promising method for the treatment of superficial bladder cancer. Although the mean initial tumor uptake was high, effective therapy of bladder tumors will require an increased retention of the cytotoxic radionuclide in tumor tissue.  (+info)

Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. (7/242)

Using a novel orthotopic MBT-2 murine bladder tumor model, we evaluated the feasibility of intravesical gene therapy utilizing a cationic liposome, DMRIE/DOPE. Superficial bladder tumors were consistently established by intravesical instillation of 5x10(5) MBT-2 cells in syngeneic C3H female mice. In situ gene transfer to bladder tumors was accomplished via intravesical instillation of plasmid DNA/DMRIE/DOPE lipoplex. Beta-Galactosidase (beta-gal) gene expression was preferentially evident in bladder tumors and was present for at least 7 days after a single 30 min in situ transfection. Murine interleukin-2 (IL-2) gene was used for treatment of 3-day-old pre-established bladder tumors. Forty percent of animals treated with IL-2 gene were completely free of tumors by 60 days following the initial tumor implantation, while all control groups treated with beta-gal gene died. Those animals initially cured of pre-established tumors were completely resistant to a subsequent tumor re-challenge and their splenocyte-derived cytotoxic T lymphocytes were shown to be specific to MBT-2 cells, indicating that immunological memory against MBT-2 tumors was elicited by the treatment. These results demonstrate the possibility of an effective clinical application of this in situ intravesical IL-2 gene delivery system to high-risk superficial bladder tumors, obviating a need for tumor procurement and ex vivo gene transfer.  (+info)

Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms. (8/242)

The local immune response to mycobacteria is complex, but mycobacterial antigen presentation by phagocytes to T helper cells is the pivotal interaction. Bacille Calmette-Guerin (BCG) vaccination is associated with the development of antituberculosis immunity but not necessarily with antitumor immunity. Animal studies have shown that an intact host immune system is required for the antitumor activity of BCG. Immunosuppressed and, particularly, T cell-depleted individuals fail to respond to BCG immunotherapy. Clinical and laboratory evidence suggest that the antitumor activity is concentrated at the site of BCG administration, which reinforces the view that local immune mechanisms are responsible for this phenomenon.  (+info)

A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of...
A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer Academic Article ...
http://vivo.med.cornell.edu/display/pubid0023102588
The effect of mitomycin C on superficial bladder cancer<...
TY - JOUR. T1 - The effect of mitomycin C on superficial bladder cancer. AU - Soloway, M. S.. AU - Murphy, W. M.. AU - DeFuria, M. D.. AU - Crooke, S.. AU - Finebaum, P.. PY - 1981/1/1. Y1 - 1981/1/1. N2 - A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg., was evaluated in 16 patients with superficial bladder cancer (stages O and A). Cystoscopically documented tumor was destroyed completely in 11 patients (69 per cent), while 3 patients exhibited partial tumor regression. Two patients had only multifocal, grade 3 carcinoma in situ and both had a complete response with negative biopsies and cytology at the 12-week evaluation. Toxicity was minimal. Further data, including longer followup, are needed to define the potentially promising role of this agent in the over-all management of superficial bladder cancer.. AB - A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg., was evaluated in 16 patients with superficial bladder cancer ...
https://miami.pure.elsevier.com/en/publications/the-effect-of-mitomycin-c-on-superficial-bladder-cancer
Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure
Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure Academic Article ...
http://vivo.med.cornell.edu/display/pubid84888640688
Altmetric - Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for...
Despite local therapies, commonly transurethral resection (TUR) followed by adjuvant treatments, non-muscle-invasive bladder cancer (NMIBC) has a high rate of recurrence and progression. Intravesical Bacillus Calmette-Guérin (BCG) has been shown to reduce recurrence and progression in people with NMIBC following TUR, however many people do not respond to treatment, have recurrence shortly after, or cannot tolerate standard-dose therapy. The potential for synergistic antitumour activity of interferon (IFN)-alpha (α) and BCG provides some rationale for combination therapy for people who do not tolerate or respond to standard-dose BCG therapy. To assess the effects of intravesically administered BCG plus IFN-α compared with BCG alone for treating non-muscle-invasive bladder cancer. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 8, 2016), MEDLINE (OvidSP) (1946 to 2016), Embase (OvidSP) (1974 to 2016), ClinicalTrials.gov, the World Health Organization ...
https://cochrane.altmetric.com/details/17131630
Clinical Application of the Adenosine Triphosphate-based Response Assay in Intravesical Chemotherapy for Superficial Bladder...Clinical Application of the Adenosine Triphosphate-based Response Assay in Intravesical Chemotherapy for Superficial Bladder...
Clinical Application of the Adenosine Triphosphate-based Response Assay in Intravesical Chemotherapy for Superficial Bladder Cancer Adenosine triphosphate;chemotherapy response assay;superficial bladder cancer; Objective: To investigate correlations between adenosine triphosphate chemotherapy response assay (ATP-CRA) and clinical outcomes after ATP-CRA-based chemotherapy for drug selection in patients receiving intravesical chemotherapy to prevent recurrence of superficial bladder cancer after surgery. Methods: The chemosensitivities of 12 anticancer drugs were evaluated, including 5-Fu ADM, and EPI, using ATP-CRA and primary tumor cell culture in 54 patients. In addition, a further 58 patients were treated according to clinical experience. Differences in post-chemotherapeutical effects between drug sensitivity assay and experience groups were compared. Results: The evaluable rate of the test was 96.3%, the clinical effective rate was 80.8%, the sensitivity rate was 97.6% (41/42), the specificity was
http://koreascience.or.kr/article/JAKO201218552489188.page
Emerging Immunotherapy Options for BCG-unresponsive Non-muscle-invasive Bladder CancerEmerging Immunotherapy Options for BCG-unresponsive Non-muscle-invasive Bladder Cancer
Request a copy of Emerging Immunotherapy Options for BCG-unresponsive Non-muscle-invasive Bladder Cancer., a 21st Century Oncology physician publication.
https://www.21co.com/physician-publication/0508201902/
Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC) - Full Text View -...Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC) - Full Text View -...
Bladder cancer is the fourth and eighth most common malignancy among men and women, respectively. About 75% of bladder cancers are diagnosed as non muscle-invasive and according to specific tumor-stage and grade characteristics, intravesical immunotherapy with Bacillus Calmette-Guérin (BCG) is used to prevent recurrence and/or progression. However, BCG immunotherapy is associated with significant adverse events and treatment failure may occur in 30-40% of cases, hence the necessity for alternative therapies. In an orthotopic MB49 mouse bladder cancer model, another bacterial vaccine (Ty21a/Vivotif) turned out to be more effective than BCG for inducing tumor regression and mice survival upon intravesical instillation; and potentially safer because Ty21a bacteria did not infect/persist in any mice tissues nor in human bladder explants or cell lines, in contrast to BCG. Ty21a/Vivotif has been used in the last 30 years in millions of individuals as an oral typhoid vaccine with a high safety record. ...
https://clinicaltrials.gov/ct2/show/NCT03421236
Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel...Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel...
Non-muscle-Invasive Bladder cancer is mainly treated by tumor resection (Trans Urethral Resection - TUR), followed by series of intravesical instillations of prophylactic chemotherapeutic drugs as Mitomycin C (MMC).This treatment approach is limited due to rapid dilution the chemotheraputic drug by the incoming urine and clearance by urination.. TheraCoat core technology is based on a reverse thermal (low viscosity at 5°C) degradable gel (TC-3)for MMC retention in the urinary bladder.. Prior to instillation, the TC-3 hydrogel,in a liquid state, is mixed with MMC.TC-3 mixed with MMC is instilled to the bladder by a catheter.Following gel insertion to the bladder, the gel solidifies and forms a drug reservoir inside the bladder. Upon contact with urine the gel dissolves and is cleared out from the bladder.. Intravesical MMC using TheraCoat gel is expected to increase treatment efficiency due to prolongation of treatment duration and consequently improving bladder exposure to MMC. ...
https://clinicaltrials.gov/ct2/show/NCT01648010
Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non-muscle-invasive...Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non-muscle-invasive...
Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non-muscle-invasive bladder cancer. Primary producers of BCG announced shortages within the last decade, leading to a worldwide shortage. We review the literature examining the BCG shortage and propose solutions to cope with this problem.
https://ndm.medsci.ox.ac.uk/publications/973114
Best Intravesical Chemotherapy Doctor in Delhi NCR, Intravesical Chemotherapy Doctors | CredihealthBest Intravesical Chemotherapy Doctor in Delhi NCR, Intravesical Chemotherapy Doctors | Credihealth
Find the best intravesical chemotherapy doctors in Delhi NCR. Get guidance from medical experts to select intravesical chemotherapy specialist in Delhi NCR from trusted hospitals - credihealth.com
https://www.credihealth.com/doctors/delhi-ncr/intravesical-chemotherapy
Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot studyPrevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study
In this preliminary study, bladder instillations of HA had a significant effect on the rate of UTI in women with a history of recurrent UTIs. The bladder instillation of HA is an acceptable and promising therapeutic alternative in patients with recurrent UTI. Expanded placebo controlled clinical tri …
https://pubmed.ncbi.nlm.nih.gov/15180619/?dopt=Abstract
SIU 2019: Changing the Paradigm in Intravesical Therapy for NMIBCSIU 2019: Changing the Paradigm in Intravesical Therapy for NMIBC
SIU 2019 intravesical therapy for non-muscle invasive bladder cancer, BCG treatment, Hyperthermic intravesical chemotherapy, TURBT, KEYNOTE 057 trial, VISTA trial, gemcitabine and docetaxel, NMIBC patients, Instiladrin, Nadofaragene firadenovec, Adstiladrin
https://www.urotoday.com/conference-highlights/siu-2019/siu-2019-bladder/115947-siu-2019-changing-the-paradigm-in-intravesical-therapy-for-nmibc.html
Enhanced urothelial ATP release and contraction following intravesical by Stanley Kang, Catherine M. McDermott et al.Enhanced urothelial ATP release and contraction following intravesical by Stanley Kang, Catherine M. McDermott et al.
Intravesical administration of the cytotoxic drug doxorubicin is a common treatment for superficial carcinoma of the bladder, but it is associated with significant urological adverse effects. The aim of this study was to identify doxorubicin-induced changes in the local mechanisms involved in regulating bladder function. As a model of intravesical doxorubicin administration in patients, doxorubicin (1 mg/mL) was applied to the luminal surface of porcine bladders for 60 min. Following treatment, the release of urothelial/lamina propria mediators (acetylcholine (Ach), ATP and prostaglandin E2 (PGE2) and contractile responses of isolated tissue strips was investigated. Doxorubicin pretreatment did not affect contractile responses of detrusor muscle to carbachol, but did enhance neurogenic detrusor responses to electrical field stimulation (219 % at 5 Hz). Contractions of isolated strips of urothelium/lamina propria to carbachol were also enhanced (30 %) in tissues from doxorubicin pretreated bladders.
http://epublications.bond.edu.au/hsm_pubs/907/
Plus itPlus it
Intravesical treatment of superficial bladder cancer is done to prevent tumor recurrence after successful local surgical resection and to eradicate residual disease. Various intravesical chemotherapeutic agents, such as thiotepa, doxorubicin, and mitomycin, have been the therapeutic treatment of choice for years; however, these agents achieved short remissions with a net durable benefit for ∼7% to 14% of patients ( 26). More unconventional forms of treatment, such as immunotherapy, were introduced in the last few decades due to unsatisfactory chemotherapy results, where one of the most successful therapies for superficial bladder cancer and carcinoma in situ of the bladder is intravesical administration of Mycobacterium bovis bacillus Calmette-Guerin (BCG; ref. 27). However, this therapy has also displayed limited success because 25% to 40% of the patients never respond to BCG ( 28, 29). The development of therapeutic regimens that offer potent tumoricidal activity but no toxic side effects to ...
http://cancerres.aacrjournals.org/content/66/1/499
Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non...Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non...
A look at the following clinical trial: Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) (NMIBC TURBT HG).
http://www.renalandurologynews.com/bladder-cancer-clinical-trials/evaluating-the-effect-of-pre-turbt-intravesical-instillation-of-mitomycin-c-mmc-mixed-with-tc-3-gel-in-patients-with-non-muscle-invasive-bladder-cancer-nmibc-nmibc-turbt-hg/article/292820/
Background This study aimed to judge the behavior of non-muscle-invasive bladder - Engineering a Therapeutic Lectin by...Background This study aimed to judge the behavior of non-muscle-invasive bladder - Engineering a Therapeutic Lectin by...
Background This study aimed to judge the behavior of non-muscle-invasive bladder cancer (NMIBC) in patients submitted to transurethral bladder resection (TURB) comparing subjects in chronic therapy with aspirin, statins, or both drugs to untreated ones. high stage disease (T1) attained the amount of unbiased risk aspect for the incident of the recurrence. When sufferers were stratified based on the different treatment; sufferers treated with statins (Group B) provided an higher level of failing (56/91 sufferers; 61.5%) in comparison with Group A (42/98 sufferers; 42.9%), Group C (56/98; 57.1%) and (133/287 sufferers; 46.3%). This difference corresponds to a big change in recurrence failing free success (p?=?0.01). Conclusions Our outcomes claim that long-term treatment with aspirin in sufferers with NMIBC might are likely involved on reducing the chance of tumor recurrence. On the other hand, in our analysis data from statins and mixture treatment groups demonstrated increased recurrence prices. ...
http://www.antiviralbiologic.com/2018/12/08/background-this-study-aimed-to-judge-the-behavior-of-non-muscle-invasive-bladder/
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle...Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle...
This randomized clinical trial compares the effect of immediate postresection intravesical instillation of gemcitabine vs instillation of saline on cancer recur
https://jamanetwork.com/journals/jama/article-abstract/2680547
Sequential BCG and electromotive mitomycin versus BCG alone for high- risk superficial bladder cancer: a randomised controlled...
Background The rationale for combining anticancer drugs has not been applied consistently to use of intravesical agents for treatment of superficial bladder cancer, for which immunotherapeutic BCG and chemotherapeutic mitomycin seem to be a potentially effective combination. We aimed to do a prospective, randomised comparison of BCG alone with that of sequential BCG and electromotive mitomycin in patients with stage pT1 bladder cancer. Methods After transurethral resection and multiple biopsies, 212 patients with stage pT1 bladder cancer were randomly assigned to: 81 mg BCG infused over 120 min once a week for 6 weeks (n=105); or to 81 mg BCG infused over 120 min once a week for 2 weeks, followed by 40 mg electromotive mitomycin (intravesical electric current 20 mA for 30 min) once a week as one cycle for three cycles (n=107). Complete responders underwent maintenance treatment: those assigned BCG alone had one infusion of 81 mg BCG once a month for 10 months, and those assigned BCG and ...
https://research.unipg.it/handle/11391/40215
Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese urological cancer...Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese urological cancer...
Long-term results were analyzed in terms of tumor progression and survival in patients with superficial bladder cancer who were enrolled in the second intravesical chemoprophylactic study of the...
https://link.springer.com/article/10.1007/BF00686935
Intravesical Therapy for Bladder CancerIntravesical Therapy for Bladder Cancer
Intravesical therapy is a treatment that is put directly into the bladder (through a catheter) rather than being given by mouth or injected into a vein.
https://www.cancer.org/cancer/bladder-cancer/treating/intravesical-therapy.html
Bay Urology, Tauranga : Managing all Urological Conditions : Intravesical BCG Treatment
Intravesical BCG Treatment   BCG placed into the bladder following the diagnosis of bladder cancer has been shown to decrease the rate of tumour recurrence but more importantly it decreases the rate of tumour progression - ie: it can prevent a superficial cancer from turning into a more serio
https://www.bayurology.co.nz/intravesical-bcg-treatment
Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder<...
TY - JOUR. T1 - Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. AU - Kluth, Luis A.. AU - Xylinas, Evanguelos. AU - Crivelli, Joseph J.. AU - Passoni, Niccolo. AU - Comploj, Evi. AU - Pycha, Armin. AU - Chrystal, James. AU - Sun, Maxine. AU - Karakiewicz, Pierre I.. AU - Gontero, Paolo. AU - Lotan, Yair. AU - Chun, Felix K H. AU - Fisch, Margit. AU - Scherr, Douglas S.. AU - Shariat, Shahrokh F.. PY - 2013/8. Y1 - 2013/8. N2 - Purpose: To our knowledge the impact of body mass index on oncologic outcomes in nonmuscle invasive bladder cancer has not been evaluated. We hypothesized that higher body mass index is associated with worse outcomes in patients with clinical primary T1 high grade urothelial carcinoma of the bladder. Materials and Methods: We retrospectively analyzed data from 892 patients with primary nonmuscle invasive bladder cancer from 7 centers. Patients were treated with transurethral resection of the bladder with or ...
https://utsouthwestern.pure.elsevier.com/en/publications/obesity-is-associated-with-worse-outcomes-in-patients-with-t1-hig
Effect of Supplemental Omega-3 Fatty Acids in Patients with Superficial Bladder Cancer After Transurethral Resection: A...Effect of Supplemental Omega-3 Fatty Acids in Patients with Superficial Bladder Cancer After Transurethral Resection: A...
P.I.: Satia, Jessie A Department: Nutrition and Epidemiology Title: Effect of Supplemental Omega-3 Fatty Acids in Patients with Superficial Bladder Cancer After Transurethral Resection: A Randomized Trial
http://unclineberger.org/ucrf/past-innovation-awards/indec2008satia
A RARE COMPLICATION OF BCG IMMUNOTHERAPY | CBU International Conference Proceedings
Barmoshe S, et al. (2004). Prognosis of T1G3 tumors: clinical factors. Eur Urol Suppl. 3:73-8. Bernini L, et al (2013). Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature. Autoimmun Rev. 12(12):1150-1159 Brausi M, et al. (2014). Side effects of bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 65(1):69-76. Decaestecker K, et al. (2015). Managing the adverse events of intravesical bacillus Calmette-Guérin therapy. Res Rep Urol. 7: 157-163. Herr HW, et al (1989). Superficial bladder cancer treated with bacillus Calmette-Guérin: A multivariate analysis of factors affecting tumor progression. J Urol. 141:22-9 Hogarth M B, et al. (2000). Reiters syndrome following ...
https://ojs.journals.cz/index.php/CBUIC/article/view/1061
Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical...Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
https://www.ncbi.nlm.nih.gov/pubmed/12900006
Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction...Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction...
Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohm RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000; 163: 1124-9 ...
http://onlinelibrary.wiley.com/doi/10.1002/ijc.11352/references?globalMessage=0
Diagnosis and management of superficial bladder cancer<...
TY - JOUR. T1 - Diagnosis and management of superficial bladder cancer. AU - Soloway, M. S.. PY - 1989/1/1. Y1 - 1989/1/1. UR - http://www.scopus.com/inward/record.url?scp=0024435009&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0024435009&partnerID=8YFLogxK. M3 - Article. C2 - 2549605. AN - SCOPUS:0024435009. VL - 5. SP - 247. EP - 254. JO - Journal of Surgical Oncology. JF - Journal of Surgical Oncology. SN - 0022-4790. IS - 4. ER - ...
https://miami.pure.elsevier.com/en/publications/diagnosis-and-management-of-superficial-bladder-cancer
Bladder Cancer - Clinical Pain AdvisorBladder Cancer - Clinical Pain Advisor
New chemotherapeutic agents undergoing evaluation in prospective clinical trials include vinflunine, ixabepilone as well as others. 3. Immunotherapy for patients with metastatic or unresectable bladder cancer The role of immunotherapy has long been established in non-muscle-invasive bladder cancer. The localized inflammatory response to intravesical BCG appears to be the source of its anti-tumor activity. For advanced or metastatic urothelial carcinomas, there is now an established role for immune checkpoint inhibitors. Currently, 5 antibodies targeting the PD1/PD-L1 axis are FDA approved for this indication. The PD-1 inhibitor pembrolizumab is approved for the treatment of patients with advanced or metastatic urothelial carcinomas who have progressed on or following prior platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. This approval is based on improved overall survival (OS) with pembrolizumab compared to cytotoxic chemotherapy. ...
https://www.clinicalpainadvisor.com/home/decision-support-in-medicine/oncology/bladder-cancer/
Immuno-Oncology | The MD Anderson Manual of Medical Oncology, 3e | AccessHemOnc | McGraw-Hill MedicalImmuno-Oncology | The MD Anderson Manual of Medical Oncology, 3e | AccessHemOnc | McGraw-Hill Medical
The ability of the immune system to recognize and eradicate cancer was first postulated in the 19th century; however, proof of principle remained elusive until the 20th century. The effect of infection on tumor regression was observed as early as 1884 by Anton Chekov (1); following this, William Coley developed a mixture of killed bacteria that were used to treat various types of cancer between the 1890s and 1960s with mixed clinical benefit. In addition, the concept of using bacterial elements was validated with Food and Drug Administration (FDA) approval of intravesical administration of BCG, which is an FDA-approved therapy that leads to nonspecific inflammatory immune responses and clinical benefit for patients with superficial bladder cancer (2). The discovery of the major histocompatibility complex (MHC) and T-cell receptor (TCR) in the 1980s provided insight into T-cell function that led to a number of clinical trials (3,4). Unfortunately, many of the early clinical trials failed due to ...
http://hemonc.mhmedical.com/content.aspx?bookid=1772§ionid=121902518
MP08-11: Switching of bacillus Calmette-Guérin (BCG) stra ... ide effects in patients with BCG-relapsing tumor | AUA UniversityMP08-11: Switching of bacillus Calmette-Guérin (BCG) stra ... ide effects in patients with BCG-relapsing tumor | AUA University
View Poster. INTRODUCTION. To investigate the clinical efficacy and safety of switching of BCG strain at the second BCG therapy in patients with BCG-relapsing non-muscle-invasive bladder tumor, defined as recurrence after achieving a disease-free status for 6 months.. METHODS. We retrospectively reviewed the clinicopathological characteristics of 97 patients treated with a second BCG therapy for BCG-relapsing tumor. At the initial BCG therapy, Tokyo-172 strain and Connaught strain were given in 71 (73.2%) and 26 (26.8%) patients, respectively. At the second BCG therapy, Tokyo-172 strain and Connaught strain were given in 56 (78.9%) and 15 (21.1%) patients who were initially treated with Tokyo-172 strain, and in 13 (50.0%) and 13 (50.0%) patients who were initially treated with Connaught strain, respectively. In other words, 28 (28.9%) patients were given a different BCG strain from a BCG strain given during initial BCG therapy (switching group), and 69 (71.1%) patients were given the same BCG ...
https://auau.auanet.org/content/mp08-11-switching-bacillus-calmette-gu%C3%A9rin-bcg-stra-ide-effects-patients-bcg-relapsing-tumor
Carcinoma in Situ | Profiles RNS
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, ODonnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117 ...
https://uams-triprofiles.uams.edu/profiles/display/99599
Long-lasting breaches in the bladder epithelium lead to storage dysfunction with increase in bladder PGE2 levels in the rat. -...Long-lasting breaches in the bladder epithelium lead to storage dysfunction with increase in bladder PGE2 levels in the rat. -...
Increase in bladder mucosal permeability can be reproduced by intravesical administration of protamine sulfate (PS); however, the influence of PS once administered into the bladder disappears within several days. We developed a chronic animal model of urothelial injury using PS. Insertion of a polyethylene catheter through the bladder dome was performed in female Wistar rats. The other end of the catheter was connected to an osmotic pump for continuous delivery of PS or vehicle for 2 wk. Urinary frequency (UF) and voided volume (VV) were measured in the metabolic cage. The fifth group of rats received a high dose of PS (10 mg/ml) for 2 wk and were followed for a further 2 wk without PS. The sixth group received a high dose of PS for 2 wk and loxoprofen (0.1 mg.kg(-1).day(-1)) for 4 wk. UF was increased, and VV was reduced in rats treated with a high dose of PS but not changed in rats treated with a vehicle or a low dose of PS (1 mg/ml). UF was further increased in the fifth group, while unchanged in the
https://www.semanticscholar.org/paper/Long-lasting-breaches-in-the-bladder-epithelium-le-Shioyama-Aoki/09c1b3622e826c30a415d17bcf09253faef3e671
Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with...Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with...
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting [email protected] All previous versions of the manuscript and all author responses to the reviewers are also available.. You can find further information about the peer review system here.. ...
https://bmcurol.biomedcentral.com/articles/10.1186/s12894-016-0126-x/open-peer-review
Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following...
TY - JOUR. T1 - Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. AU - Wheat, Jeffery C.. AU - Weizer, Alon Z.. AU - Wolf, J. Stuart. AU - Lotan, Yair. AU - Remzi, Mesut. AU - Margulis, Vitaly. AU - Wood, Christopher G.. AU - Montorsi, Francesco. AU - Roscigno, Marco. AU - Kikuchi, Eiji. AU - Zigeuner, Richard. AU - Langner, Cord. AU - Bolenz, Christian. AU - Koppie, Theresa M.. AU - Raman, Jay D.. AU - Fernández, Mario. AU - Karakiewizc, Pierre. AU - Capitanio, Umberto. AU - Bensalah, Karim. AU - Patard, Jean Jacques. AU - Shariat, Shahrokh F.. PY - 2012/5. Y1 - 2012/5. N2 - Objective: Carcinoma in situ (CIS) is associated with increased risk of progression when found with high-grade non-muscle-invasive bladder cancer, yet its impact is less clear in the upper urinary tract. In the current study, we evaluated the impact of concomitant CIS on recurrence-free survival and cancer-specific ...
https://moh-it.pure.elsevier.com/en/publications/concomitant-carcinoma-in-situ-is-a-feature-of-aggressive-disease-
ASCO 2018: PECULIAR: An Open Label, Multicenter, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab and Epacadostat,...ASCO 2018: PECULIAR: An Open Label, Multicenter, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab and Epacadostat,...
Kirkby Malzeard & Masham Surgeries - Library - Health A-ZKirkby Malzeard & Masham Surgeries - Library - Health A-Z
People with intermediate-risk non-muscle-invasive bladder cancer should be offered a course of at least six doses of chemotherapy. The liquid is placed directly into your bladder, using a catheter, and kept there for around an hour before being drained away.. You should be offered follow-up appointments at three months, nine months, 18 months, then once every year. At these appointments, your bladder will be checked using a cystoscopy. If your cancer returns within five years, youll be referred back to a specialist urology team.. Some residue of the chemotherapy medication may be left in your urine after treatment, which could severely irritate your skin. It helps if you urinate while sitting down and that youre careful not to splash yourself or the toilet seat. After passing urine, wash the skin around your genitals with soap and water.. If youre sexually active, its important to use a barrier method of contraception, such as a condom. This is because the medication may be present in your ...
http://www.kirkbyandmashamsurgeries.co.uk/Library/Conditions/Articles/cancer-of-the-bladder/treatment
Plus itPlus it
Background: Current treatment options for metastatic UC remain limited, and tolerability is a concern in many patients. Alterations in the fibroblast growth factor receptor (FGFR) pathway are implicated in development of non-muscle-invasive bladder cancer; FGFR3 mutations or FGFR translocations are present in ∼10-20% of patients with metastatic UC. Treatment with pan-FGFR (FGFR1-4) inhibitor JNJ-42756493 resulted in promising antitumor activity in a phase 1 trial in patients with advanced solid tumors, including 3 partial responses among 8 patients with UC (Tabernero J, et al. J Clin Oncol. 2015). Safety was manageable and as anticipated with a potent FGFR inhibitor. This phase 2 open-label study of JNJ-42756493 (NCT02365597) is being conducted to determine efficacy and safety of 2 different dose regimens in patients with metastatic or unresectable UC with specific FGFR translocations or mutations.. Methods: Eligible patients must have disease progression following chemotherapy for metastatic ...
http://cancerres.aacrjournals.org/content/76/14_Supplement/CT080
Role of IL-12 in the Induction and Potentiation of IFN-γ in Response to Bacillus Calmette-Guérin | The Journal of ImmunologyRole of IL-12 in the Induction and Potentiation of IFN-γ in Response to Bacillus Calmette-Guérin | The Journal of Immunology
BCG has been used as an antitumor agent for bladder cancer immunotherapy for over 2 decades (30). Although BCG antitumor activity has been clinically demonstrated, its successful use has been tempered by its systemic toxicity, unreliable efficacy, and prognostic unpredictability (4, 31). However, since BCG remains the most efficacious topical therapy for superficial bladder cancer, additional efforts to define an improved BCG regimen in both efficacy and safety should be pursued. Although the precise mechanism of BCG action remains to be defined, observations from both clinical and experimental studies suggest that BCG therapy requires an intact immune system, works via a localized process of stimulation, mediates an interacting network of immune cells and cytokines, and induces a nonspecific immune response (4, 31, 32, 33). As a potent immune stimulator, BCG elicits both humoral and cellular responses. However, antitumor immunity induced by intravesical BCG in bladder cancer therapy appears to ...
https://www.jimmunol.org/content/163/8/4246?ijkey=33a913da78588a81de534fcf26ec0a53c9768fa6&keytype2=tf_ipsecsha
Diphtheria Toxin-Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer | Clinical Cancer ResearchDiphtheria Toxin-Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer | Clinical Cancer Research
In this work, we present a novel use of an EGFR-directed fusion protein with a modified DT. Bladder cancer frequently overexpresses EGFR on the luminal surface, whereas such expression is uncommon on the normal urothelium. Using an orthotopic, xenograft model of bladder cancer, we showed a difference in the elimination of the implanted tumor after 2 weeks of intravesical treatment with DAB389EGF, as compared with the control DT chimeric protein (DAB388GM-CSF). Importantly, in immunocompetent mice, there was clear, generalized toxicity with the intravenous DAB389EGF treatment, but there was no evidence of histologic or generalized toxicity in the intravesically treated mice at equal doses.. While targeted agents have made significant inroads into the clinical management of most common cancer types, there is no integration of such agents into the routine treatment of urothelial carcinoma. Importantly, in most cases, the use of inhibiting a particular molecular pathway is dependent on pathway ...
http://clincancerres.aacrjournals.org/content/19/1/148?rss=1
The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer...The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer...
Purpose: We investigate the correlation of purified protein derivative (PPD) results before intravesical bacillus Calmette-Guerin (BCG) instillations with prognosis and complications of BCG. ...
https://avesis.hacettepe.edu.tr/yayin/50d67b6d-38e0-4893-b98e-0bfd06ac413f/the-predictive-value-of-purified-protein-derivative-results-on-complications-and-prognosis-in-patients-with-bladder-cancer-treated-with-bacillus-calmette-guerin
Optical diagnostics in urology: current applications and future prospects - Crow - 2003 - BJU International - Wiley Online...Optical diagnostics in urology: current applications and future prospects - Crow - 2003 - BJU International - Wiley Online...
In vivo studies have been undertaken by several groups. The equipment used is generally less complicated than for the LIAFS studies, in that the fluorescence is assessed with a standard video camera, negating the need for a fluorescence detector. Some of the early studies used a photosensitizer (Photophrin™) to induce fluorescence [4], but more recent studies have used 5-ALA, hexyl-ALA or hypericin. The route by which the agent was administered has also varied. Some authors used systemic administration of the agent, hoping that the greater tumour penetration achieved would aid the assessment of adequate resection [11]. However, the systemic use of photosensitizers is limited by skin photosensitivity and thus most studies have used intravesical instillation of the agent, which obviates this problem. 5-ALA for use by the intravesical route must be prepared freshly each day and instilled 3 h before cystoscopy. Other than occasional reports of urgency or mild bladder discomfort, the intravesical ...
http://onlinelibrary.wiley.com/doi/10.1046/j.1464-410X.2003.04368.x/full
Sodium hyaluronate & Sodium chondroitin sulphate bladder instillation - Lancashire and South Cumbria Medicines Management GroupSodium hyaluronate & Sodium chondroitin sulphate bladder instillation - Lancashire and South Cumbria Medicines Management Group
The purpose of the LMMG Lancashire Medicines Management Group is to provide a platform for a consensus decision making process relating to the use of medicines across the Lancashire NHS footprint, to ensure equity in access to medicines and optimisation of medicines use.
https://www.lancsmmg.nhs.uk/medicines-library/sodium-hyaluronate-sodium-chondroitin-sulphate-bladder-instillation/
Plus it
The most effective form of immunotherapy for solid tumours is still poorly understood. The main risks from superficial bladder cancer are that it may recur or that it may progress to invasive disease with a high mortality. Immunotherapy with live BCG vaccine was shown to be an effective treatment as long ago as 1976,1 and the vaccine is still the only intravesical agent to have been shown to reduce both of these risks.2. Factors that increase the risk of progression are high tumour grade, invasion of the lamina propria, and the presence of carcinoma in situ.3 The main indications for the use of BCG vaccine in Britain are treatment of carcinoma in situ of the bladder; treatment of residual superficial papillary tumour; and prophylaxis against recurrence of superficial tumours and against progression after resection of a tumour.. No one questions the use of BCG vaccine for diffuse carcinoma in situ. This condition is difficult to eradicate by resection--indeed, if treated by surgery alone it ...
http://www.bmj.com/content/308/6932/801
The Promise of Immune Checkpoint Blockade in Cancer Therapy - The ASCO PostThe Promise of Immune Checkpoint Blockade in Cancer Therapy - The ASCO Post
The concept of using activation of the innate immune system and an inflammatory response against a bacterial component to instigate an antitumor response was studied in the 1960s, which led to the development of intravesical bacillus Calmette-Guérin, now used in the treatment of superficial bladder cancer. Over the following decades, the promise of immunotherapy ebbed and flowed until a couple of decades ago, when researchers saw promise in T-cell activation, paving the way for a revival of immunotherapy. Today, one of the most exciting areas in immunotherapy is checkpoint blockade.. The ASCO Post recently spoke with James P. Allison, PhD, who received the 2015 Lasker-DeBakey Clinical Medical Research Award for his pioneering work in enabling T cells to attack cancer cells by removing checkpoints that normally inhibit T-cell activity.. A Career-Changing Period. Please tell the readers a bit about your career and your current position.. I came from a small town in south Texas and received both ...
http://www.ascopost.com/issues/december-25-2015/the-promise-of-immune-checkpoint-blockade-in-cancer-therapy/
Universal Pharmacy: Viagra patong thailand best ED treatmentUniversal Pharmacy: Viagra patong thailand best ED treatment
Tea leaves contain fluoride; and a bad thailand patong viagra family history affect almost half of the characteristic signs of anemia. Explosive disorder see pervasive developmental disorder characterized by misuse of industrial glycerol contaminated with small bowel can be obtained by bladder instillation for superficial bladder tumours. Birth defects are left in the evening. Acetylcholine, by acting on the left interstitium, separate from each other, to create a tissue seal. The grafts have been reported in the liver converts the cis form which is expected to produce an electrosurgical plume. [french: Literally beautiful indifference] labia majora and can be caused by blood vessels that respond to lithium. Clin chest med 2008a;26:699. May be seen. (courtesy of medgyn products.) 483 figure 14.4 comparison of various types. Tonic-clonic diagnosis are that urgent referral to a diagnosis. No studies have noted decreased perioperative morbidity and mortality. Endometrial hyperplasia with atypia, ...
https://bigsurlandtrust.org/care/viagra-patong-thailand/20/
Most recent papers with the keyword Oxygen delivery | Read by QxMDMost recent papers with the keyword Oxygen delivery | Read by QxMD
New intravesical treatment approaches for bladder cancer are needed as currently approved treatments show several side effects and high tumor recurrence rate. Our study used MB49 murine urothelial carcinoma model to evaluate oxygen encapsulated cellulosic nanobubbles as a novel agent for imaging and ultrasound guided drug delivery. In this study, we show that oxygen nanobubbles (ONB) can be propelled (up to 40 mm/s) and precisely guided in vivo to the tumor by an ultrasound beam. Nanobubble velocity can be controlled by altering the power of the ultrasound Doppler beam, while nanobubble direction can be adjusted to different desired angles by altering the angle of the beam ...
https://www.readbyqxmd.com/keyword/82691
Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer<...
TY - JOUR. T1 - Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. AU - Klatte, Tobias. AU - Xylinas, Evanguelos. AU - Rieken, Malte. AU - Kluth, Luis A.. AU - Rouprêt, Morgan. AU - Pycha, Armin. AU - Fajkovic, Harun. AU - Seitz, Christian. AU - Karakiewicz, Pierre I.. AU - Lotan, Yair. AU - Babjuk, Marko. AU - De Martino, Michela. AU - Scherr, Douglas S.. AU - Shariat, Shahrokh F.. N1 - Copyright: Copyright 2014 Elsevier B.V., All rights reserved.. PY - 2014/5. Y1 - 2014/5. N2 - Purpose ABO blood type is an established prognostic factor for several malignancies but its role in bladder urothelial carcinoma is largely unknown. We determined whether ABO blood type is associated with the outcome of transurethral resection of nonmuscle invasive bladder urothelial carcinoma. Materials and Methods We retrospectively studied ABO blood types in 931 patients with primary nonmuscle invasive bladder urothelial carcinoma treated with transurethral bladder ...
https://utsouthwestern.pure.elsevier.com/en/publications/impact-of-abo-blood-type-on-outcomes-in-patients-with-primary-non
Bladder Cancer | DASPITEBladder Cancer | DASPITE
Treatment depends on the grade and extent of invasion of the bladder cancer. In most cases, an urgent transurethral resection of bladder tumour (TURBT) is carried out, and intravesical chemotherapy to reduce the risk of recurrence.. ​. Low grade, non-muscle invasive bladder cancer (Ta). TURBT + intravesical mitomycin C at the same time. Follow-up cystoscopy 3 months and then 12 months and discharge if no recurrence. If intermediate risk, follow-up cystoscopy at 3, 9, 18 months then yearly. If recurring ,12 months, give course of 6 doses intravesical mitomycin C. ​. High grade, non-muscle invasive bladder cancer (T1). TURBT. Either intravesical BCG immunotherapy or radical cystectomy. Cystectomy if poor response to ,2 sets BCG. Follow-up cystoscopy every 3 months for 2 years, then every 6 months for 2 years, then yearly. ​. Muscle invasive bladder cancer (T2-T4). Neoadjuvant chemotherapy. Radical cystectomy or radiotherapy. Follow-up: yearly imaging and monitoring of kidney function, ...
https://www.daspite.com/bladder-cancer
Granulomatous hepatitis, choroiditis and aortoduodenal fistula complicating intravesical Bacillus Calmette-Guérin therapy: Case...Granulomatous hepatitis, choroiditis and aortoduodenal fistula complicating intravesical Bacillus Calmette-Guérin therapy: Case...
Intravesical instillation of Bacillus Calmette-Guérin (BCG) is the treatment of choice for superficial bladder carcinoma. Complications of BCG therapy include local infections and disseminated BCG infection with multiple endorgan complications. We report a case of disseminated, post-treatment BCG infection that initially presented with granulomatous hepatitis and choroiditis. After successful anti-mycobacterial therapy and resolution of the hepatic and ocular abnormalities, the patient developed an acute upper gastrointestinal hemorrhage from an aortoduodenal fistula that required emergency surgery. The resection specimen revealed multifocal, non-caseating granulomas, indicating mycobacterial involvement. This case highlights the varied end organ complications of disseminated BCG infection, and the need for vigilance even in immuno-competent patients with a history of intravesical BCG treatment.
https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-11-260
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer | Clinical Research Trial Listing (...Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer | Clinical Research Trial Listing (...
Clinical trial for Urothelial Carcinoma Bladder | bladder cancer | bladder disorder | transitional cell carcinoma of bladder | Urothelial Cancer | carcinoma of the bladder | Bladder Carcinoma | bladder tumor | urinary tract neoplasm | Urologic Cancer | Transitional Cell Carcinoma of the Bladder | Bladder Disorders , Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer
https://www.centerwatch.com/clinical-trials/listings/249778/intravesical-gemcitabine-and-docetaxel-for-bcg-na-ve-non-muscle-invasive-bladder-cancer/?&radius=50&query=invasive%20bladder%20cancer&page=5&rnk=15
Global Intravesical Bacillus Calmette Market Research Report 2017Global Intravesical Bacillus Calmette Market Research Report 2017
Global Intravesical Bacillus Calmette Market Research Report 2017 Global Intravesical Bacillus Calmette Market Research Report 2017 This report studies Intravesical Bacillus Calmette in Global market, especially - Market research report and industry analysis - 10750434
https://www.marketresearch.com/QYResearch-Group-v3531/Global-Intravesical-Bacillus-Calmette-Research-10750434/
Table 1 | Prosthetic Joint Infection due to Mycobacterium bovis after Intravesical Instillation of Bacillus Calmette-Guerin ...Table 1 | Prosthetic Joint Infection due to Mycobacterium bovis after Intravesical Instillation of Bacillus Calmette-Guerin ...
Table 1: Prosthetic Joint Infection due to |i|Mycobacterium bovis|/i| after Intravesical Instillation of Bacillus Calmette-Guerin (BCG)
https://www.hindawi.com/journals/ijmicro/2009/527208/tab1/
Recurrent verrucous carcinoma of the urinary bladder after transurethral resection followed by intravesical mitomycin, and a...
TY - JOUR. T1 - Recurrent verrucous carcinoma of the urinary bladder after transurethral resection followed by intravesical mitomycin, and a review of the literature. AU - Hassan, Masroor. AU - Qureshi, Asim. AU - Nasir, Humaira. PY - 2016. Y1 - 2016. N2 - Verrucous carcinoma (VC) is a locally invasive, nonmetastasising well differentiated variant of squamous cell carcinoma. It is very rare in the urinary bladder and mostly associated with schistosomiasis. It has a characteristic multilobular appearance with small surface projections on contrast cystogram. Owing to its bland cytology, it is a challenging diagnosis. We report a case of VC of the bladder-unrelated to schistosomiasis and involving the prostate-that recurred after transurethral resection of the tumour and prostate followed by six doses of intravesical mitomycin. To the best of our knowledge, no such case has been reported from Pakistan.. AB - Verrucous carcinoma (VC) is a locally invasive, nonmetastasising well differentiated ...
https://squ.pure.elsevier.com/en/publications/recurrent-verrucous-carcinoma-of-the-urinary-bladder-after-transu
MP08-04: Purified protein derivative skin test prio ... ts with non-muscle invasive bladder cancer (APL - 2018) | AUA UniversityMP08-04: Purified protein derivative skin test prio ... ts with non-muscle invasive bladder cancer (APL - 2018) | AUA University
View Poster. INTRODUCTION. Little is known about the clinical impact of the purified protein derivative (PPD) skin test prior to BCG therapy in patients with non-muscle invasive bladder cancer (NMIBC) treated with adjuvant BCG therapy.. METHODS. A total of 498 NMIBC patients initially treated with adjuvant BCG therapy at our institute between 1990 and 2015 were included. Of them, 320 (64.3%) had received the PPD skin test prior to BCG therapy (PPD group), while 178 (35.7%) patients had not (non-PPD group). The PPD skin test was performed 1 to 2 weeks prior to the start of adjuvant BCG therapy. We evaluated the association between PPD skin test performed or not performed and clinical outcomes including oncological outcomes and the incidence of BCG-related side effects in NMIBC patients treated with BCG therapy. RESULTS. Patients in the PPD group had a significantly higher incidence of pT1 (40.6%) and lower incidence of concomitant CIS (16.9%) as compared to those in the non-PPD group (28.1% and ...
https://auau.auanet.org/content/mp08-04-purified-protein-derivative-skin-test-prio-ts-non-muscle-invasive-bladder-cancer-apl
Mitomycin instillation medac - Slimming tea mustika ratu
The Dangers of Using Mitomycin-C The potent agent that has the power to banish haze may be able to make endothelial cells disappear, as well.. Mitomycin is FDA approved for the...Mitomycin C: mechanism of action, usefulness and limitations.. Intravesicular mitomycin is an antitumor antibiotic treatment given directly into the bladder. However, it can occur with any instillation.The purpose of this study is to compare the bladder cancer treatments, Mitomycin C (MMC) and Bacillus Calmette Guerin (BCG), to find out which is better.Mitomycin - Drug Info, Side Effects, Research, Clinical Trials. will be scheduled to receive monthly intravesical instillation for 10 months,.Mitomycin C is given as a chemotherapy,. mitomycin c intravesical Instillation. here in video we have instilled 40 mg of Mitomycin,.Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour. as well as by bladder instillation for superficial bladder tumours.. EAUN15 Guideline Intravesical ...
http://e-jual.tk/kogyp/mitomycin-instillation-medac-438.php
Influences of Different Operative Methods on the Recurrence Rate of Non-Muscle-Invasive Bladder Cancer | Urology Journal...Influences of Different Operative Methods on the Recurrence Rate of Non-Muscle-Invasive Bladder Cancer | Urology Journal...
Maurice MJ, Vricella GJ, MacLennan G, Buehner P, Ponsky LE. Endoscopic snare resection of bladder tumors: evaluation of an alternative technique for bladder tumor resection. Journal of endourology. 2012;26:614-7. Bai Y, Liu L, Yuan H, et al. Safety and efficacy of transurethral laser therapy for bladder cancer: a systematic review and meta-analysis. World journal of surgical oncology. 2014;12:301. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. European urology. 2004;46:170-6. DUTTA SC, SMITH JA, SHAPPELL SB, COFFEY CS, CHANG SS, COOKSON MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. The Journal of urology. 2001;166:490-3. Suer E, Hamidi N, Gokce MI, et al. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy. World journal of urology. 2016;34:847-51. Chen J, ...
https://journals.sbmu.ac.ir/urolj/index.php/uj/article/view/5965
Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive...
TY - JOUR. T1 - Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit.. AU - Krajewski, Wojciech AU - Moschini, Marco AU - Nowak, Łukasz AU - Poletajew, Sławomir. AU - Tukiendorf, Andrzej AU - Afferi, Luca AU - Teoh, Jeremy AU - Muilwijk, Tim AU - Joniau, Steven AU - Tafuri, Alessandro AU - Antonelli, Alessandro AU - Gozzo, Alessandra AU - Mari, Andrea. AU - Di Trapani, Ettore. AU - Hendricksen, Kees AU - Alvarez-Maestro, Mario AU - Rodriguez Serrano, Andrea. AU - Simone, Giuseppe AU - Zamboni, Stefania AU - Simeone, Claudio AU - Marconi, Maria Cristina. AU - Mastroianni, Riccardo AU - Ploussard, Guillaume AU - Rajwa, Paweł AU - Laukhtina, Ekaterina AU - Zdrojowy-Wełna, Aleksandra. AU - Kołodziej, Anna AU - Paradysz, Andrzej AU - Tully, Karl AU - Krajewska, Joanna AU - Piszczek, Radosław AU - Xylinas, Evanguelos AU - Zdrojowy, Romuald PY - 2020/10/15. Y1 - ...
https://moh-it.pure.elsevier.com/en/publications/restaging-transurethral-resection-of-bladder-tumours-after-bcg-im-2
Preoperative predictive factors of carcinoma in situ in the normal-appearing mucosa in patients who underwent an initial...
BACKGROUND: Although few studies evaluated the significance of random biopsies under white light cystoscopy (WLC) in patients with non-muscle-invasive bladder cancer (NMIBC), the findings are controversial.. AIM: This aim of this study was to evaluate what kind of preoperative covariates were useful as predictive factors in detecting carcinoma in situ (CIS) from normal-appearing mucosa using random bladder biopsies under WLC.. METHODS AND RESULTS: A total of 229 patients with NMIBC underwent initial TUR followed by random biopsies under WLC at Red Cross Takayama Hospital between 2007 and 2016. These patients underwent TUR with complete resection of intravesical visible tumors followed by random biopsies of normal-appearing mucosa. In this study, random bladder biopsies of normal-appearing urothelial mucosa, excluding abnormal mucosa, were carried out with a cold punch in the selected intravesical sites. The covariates included age, gender, the urine cytology result, presence of an abnormal ...
https://health.omgcb.com/bladder-cancer/9656/preoperative-predictive-factors-of-carcinoma-in-situ-in-the-normal-appearing-mucosa-in-patients-who-underwent-an-initial-transurethral-resection-for-non-muscle-invasive-bladder-cancer-under-white-light-cystoscopy.html
G9a Inhibition Has Antitumor Activity in Bladder Cancer | Cancer DiscoveryG9a Inhibition Has Antitumor Activity in Bladder Cancer | Cancer Discovery
There are limited established therapies for bladder cancer, which can be lethal if it reaches advanced stages and invades surrounding muscle tissue. Segovia, San José-Enériz, Munera-Maravilla, and colleagues found that expression of the histone methyltransferase G9a, suggested in prior studies to be a bladder cancer oncoprotein, was higher in human non-muscle-invasive bladder cancer tumors than in adjacent healthy tissue, and higher levels of the G9a mRNA and protein were correlated with increased chance of bladder cancer recurrence. CM-272, a G9a/DNMT inhibitor, inhibited cell proliferation in some bladder cancer cell lines, and cell lines resistant to CM-272 had mutations in PIK3CA. Because G9a and EZH2 coregulate H3K27me3 and activating mutations in PIK3CA reduce EZH2 and H3K27me3 in bladder cancer, CM-272 resistance may be related to EZH2 activity; supporting this, PIK3CA-mutant bladder cancer cells had decreased EZH2 levels, and PIK3CA-mutant bladder cancer cells exhibited EZH2 ...
https://cancerdiscovery.aacrjournals.org/content/early/2019/07/12/2159-8290.CD-RW2019-105.full
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment | Protocol (Translated to Spanish)An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment | Protocol (Translated to Spanish)
El establecimiento de un modelo de tumor de vejiga ortotópica para evaluar los efectos antitumorales de SARNA intravesical entrega y el ...
https://www.jove.com/video/4207/un-modelo-de-tumor-vesical-ortotpica-y-la-evaluacin-de-tratamiento?language=Spanish
Supplementary Material for: Efficacy and Safety of Transurethral Laser Surgery Versus Transurethral Resection for Non-Muscle...Supplementary Material for: Efficacy and Safety of Transurethral Laser Surgery Versus Transurethral Resection for Non-Muscle...
Supplementary Material for: Efficacy and Safety of Transurethral Laser Surgery Versus Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A Meta-Analysis and Systematic Review
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Efficacy_and_Safety_of_Transurethral_Laser_Surgery_Versus_Transurethral_Resection_for_Non-Muscle-Invasive_Bladder_Cancer_A_Meta-Analysis_and_Systematic_Review/12376946
Intravesical hyaluronic acid - effective option in the treatment of hemorrhagic cystitis | InstylanIntravesical hyaluronic acid - effective option in the treatment of hemorrhagic cystitis | Instylan
Hemorrhagic cystitis - an inflammatory disease of the bladder with a complex etiology. The frequency of this pathology has increased substantially due to the increase in the number of patients undergoing radiation therapy for malignant neoplasms of the pelvic organs. The development of rational treatment of hemorrhagic cystitis is a difficult problem. Given the pathogenetic basis of disease, it is assumed that the optimal methods of treatment should be aimed at the regeneration of glycosaminoglycan mucosal layer of the bladder. The article presents the results of a study of effectiveness of intravesical instillation of hyaluronic acid in the treatment of hemorrhagic cystitis. ...
http://instylan.com/es/2017/08/16/ru-primenenie-gialuronovoj-kisloty-effektivnaya-optsiya-lecheniya-luchevogo-gemorragicheskogo-tsistita/
Basic Concepts in Bladder Cancer Immunotherapy | Gotoper.comBasic Concepts in Bladder Cancer Immunotherapy | Gotoper.com
Introduction. On May 18, 2016, atezolizumab became the first anti-PD-L1 inhibitor to gain FDA approval for use in patients with advanced urothelial carcinoma. Approval of an additional 4 anti-PD-1/ PD-L1 inhibitors would follow.1 These exciting new treatments take advantage of interactions between cancer cells and their hosts immune system, thereby offering patients an alternative to cytotoxic therapies. Widespread use of these novel agents requires that clinicians gain familiarity with the growing field of immunotherapy. In this review, we discuss basic concepts for understanding the immune systems interactions with malignant cells, as well as report on the currently available immunotherapies in the treatment of bladder cancer.. The susceptibility of bladder cancer to immune-mediated destruction is not a new concept, as demonstrated by the use, decades ago, of Bacillus Calmette-Guérin (BCG) by urologists for non-muscle-invasive bladder cancer. Based on an observation that tuberculosis ...
http://www.gotoper.com/publications/ajho/2017/2017october/basic-concepts-in-bladder-cancer-immunotherapy
Autophagy and urothelial carcinoma of the bladder: A review<...
TY - JOUR. T1 - Autophagy and urothelial carcinoma of the bladder. T2 - A review. AU - Chandrasekar, Thenappan. AU - Evans, Christopher P. PY - 2016. Y1 - 2016. N2 - The incidence of urothelial carcinoma of the urinary bladder (bladder cancer) remains high. While other solid organ malignancies have seen significant improvement in morbidity and mortality, there has been little change in bladder cancer mortality in the past few decades. The mortality is mainly driven by muscle invasive bladder cancer, but the cancer burden remains high even in nonmuscle invasive bladder cancer due to high recurrence rates and risk of progression. While apoptosis deregulation has long been an established pathway for cancer progression, nonapoptotic pathways have gained prominence of late. Recent research in the role of autophagy in other malignancies, including its role in treatment resistance, has led to greater interest in the role of autophagy in bladder cancer. Herein, we summarize the literature regarding the ...
https://ucdavis.pure.elsevier.com/en/publications/autophagy-and-urothelial-carcinoma-of-the-bladder-a-review
Browse In pH (blood), Hyperkalaemia | EDM Case ReportsBrowse In pH (blood), Hyperkalaemia | EDM Case Reports
Durvalumab, a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules, is increasingly used in advanced neoplasias. Durvalumab use is associated with increased immune-related adverse events. We report a case of a 55-year-old man who presented to our emergency room with hyperglycaemia after receiving durvalumab for urothelial high-grade non-muscle-invasive bladder cancer. On presentation, he had polyuria, polyphagia, nausea and vomiting, and laboratory test revealed diabetic ketoacidosis (DKA). Other than durvalumab, no precipitating factors were identified. Pre-durvalumab blood glucose was normal. The patient responded to treatment with intravenous fluids, insulin and electrolyte replacement. Simultaneously, he presented a thyroid hormone pattern that evolved in 10 weeks from subclinical hyperthyroidism (initially attributed to iodinated contrast used in a previous computerised tomography) to ...
https://edm.bioscientifica.com/browse?access=user&pageSize=10&sort=datedescending&t=investigation_303&t0=condition_158
Intravesical therapy | Jeremy Ockrim - Consultant Urological Surgeon
As specialists in the treatment of bladder problems, Mr Jeremy Ockrim offers medically advanced treatments, many of which are not widely available in the UK. This means Mr Jeremy Ockrim is able to find effective solutions for patients whose previous treatment may not have been successful.
http://www.jeremyockrim.co.uk/2195-2/
Toxicology and Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Dogs | Clinical Cancer ResearchToxicology and Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Dogs | Clinical Cancer Research
It is estimated that the incidence of bladder cancer in the United States in 1999 will be ∼54,200 new cases with an expected mortality of 12,100 (1) . In men, bladder cancer remains the fourth most common malignancy and will account for 6% of all cancer cases, whereas in women, it is the eighth most common malignancy and will account for 3% of all cancers (1) . Furthermore, the incidence of bladder cancer has increased in the United States by 36% from 1956 to 1990 (2) . Presently, 74% of bladder cancers are superficial at initial diagnosis, 18% are advanced but confined to the pelvis, whereas only 3% have metastasized (2) . However, up to 30% of all patients with superficial disease will develop muscle invasive tumors within 5 years (3 , 4) .. Treatment of superficial disease aims to eradicate existing disease and to prevent tumor recurrence and/or progression to muscle invasion and metastasis. Patients treated by transurethral resection alone have only a 49% chance of remaining free of ...
http://clincancerres.aacrjournals.org/content/5/9/2629.long
April 2015 ~ Valley OBGYNApril 2015 ~ Valley OBGYN
During a bladder instillation, also called a bladder wash or bath, the bladder is filled with a solution that is held for varying periods of time, averaging 10 to 15 minutes, before being emptied. The only drug approved by the U.S. Food and Drug Administration (FDA) for bladder instillation is Dimethyl Sulfoxide (DMSO, RIMSO-50). DMSO treatment involves guiding a narrow tube called a catheter up the urethra into the bladder. A measured amount of DMSO is passed through the catheter into the bladder, where it is retained for about 15 minutes before being expelled. Treatments are given every week or two for 6 to 8 weeks and repeated as needed. Most people who respond to DMSO notice improvement 3 or 4 weeks after the first 6- to 8-week cycle of treatments. Highly motivated patients who are willing to catheterize themselves may, after consultation with their doctor, be able to have DMSO treatments at home. Self-administration is less expensive and more convenient than going to the doctors office. ...
https://valleyob.blogspot.com/2015/04/
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder - CareAcross
The investigators intend to evaluate the safety and toxicity profile of intravesically administered multidrug regimen of Cabazitaxel, Cisplatin and Gemcitabine in treatment refractory Transitional Cell Carcinoma.The investigators propose to conduct a combined phase I trial to assess the safety, toxicity, and efficacy of a novel multidrug intravesical regimen consisting of Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of BCG resistant non-muscle invasive urothelial carcinoma of the bladder. This phase I trial will have a combined dose and cycle-escalation scheme with enrollment of up to 24 patients.
https://www.careacross.com/clinical-trials/trial/NCT02202772
Mitomycin C - WikipediaMitomycin C - Wikipedia
Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour activity. It is given intravenously to treat upper gastro-intestinal cancers (e.g. esophageal carcinoma), anal cancers, and breast cancers, as well as by bladder instillation for superficial bladder tumours. It causes delayed bone marrow toxicity and therefore it is usually administered at 6-weekly intervals. Prolonged use may result in permanent bone-marrow damage. It may also cause lung fibrosis and renal damage. Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to ...
https://en.wikipedia.org/wiki/Mitomycin_C
Antibiotic prophylaxis with 3-day course of prulifoxacin 600 mg in superficial bladder cancer patients undergoing Bacillus...Antibiotic prophylaxis with 3-day course of prulifoxacin 600 mg in superficial bladder cancer patients undergoing Bacillus...
Restricted Access Oops, it looks like you dont have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following. ...
http://adisinsight.springer.com/trials/700036710?error=cookies_not_supported&code=2d92df52-9691-472b-a25c-8f1f730df33a
Bladder CancerBladder Cancer
Patients diagnosed with bladder cancer are examined cystoscopically and transurethral tumor resection (TUR) is performed. This procedure is totally endoscopic without any incision to the body. Pathologic specimen is examined by pathologists. This will identify the tumor depth and its histopathological subtype.. Before making any decision on the treatment plan, the tumor location, its pathological grade, the presence of perivesical invasion, the patient age and other comorbidites should be evaluated.. Most bladder cancers are limited to the inner epithelial layer without muscular layer involvement at the time of diagnosis. Those are called the superficial tumors of bladder. High-grade superficial tumors require additional intravesical immune therapies such as BCG (tuberculosis vaccine) or chemotherapy. Intravesical BCG treatment will trigger immunity against tumor cells. With regards to recurrence, periodical cystoscopy and imaging studies are needed in terms of follow-up.. Muscle-invasive ...
https://www.lutfitunc.com/en/bladder-cancer
Paper Alert 7 | Bladder CancerPaper Alert 7 | Bladder Cancer
Between 15 and 20% of patients with newly diagnosed urothelial cancer (UC) of the bladder will have high grade (HG) non-muscle invasive (NMI) disease including carcinoma-in-situ (CIS) and stage Ta and T1 tumors [1]. After transurethral resection of the cancer (TURBT), patients may undergo re-TURBT, but if no muscle invasive (MI) cancer is found most will receive an induction course of 6 weekly intravesical instillations of Bacillus Calmette Guerin (BCG).
https://bladdercancerjournal.com/paper-alert-7
Plus itPlus it
Bladder cancer poses a serious public health challenge, given the high rate of incidence and the cost for managing this disease. Muscle-invasive tumors are the most difficult to treat and pose a significant threat to life, due to their metastatic nature. Approximately 80% of human bladder cancers are non-muscle invasive when first diagnosed and are usually treated by transurethral tumor resection. But 50% to 80% of patients experience cancer recurrence. To prevent or delay tumor recurrence, intravesical therapy with Bacillus Calmette-Guerin (BCG) is frequently used as an adjunctive after TUR. Other agents such as mitomycin, gemcitabine, and pirarubicin are being investigated clinically (27-29). However, BCG may not be effective in all patients, have significant side effects such as infection by BCG, and require urethral catheterization. Therefore, there is a need to identify agents for primary and secondary prevention of bladder cancer. There has been significant progress in the molecular ...
http://cancerpreventionresearch.aacrjournals.org/content/9/1/53
Main Drugstore: Viagra not working first time express pills!
Rarely, more serious, first working viagra not time some- possible. Receiving large doses it is thought to play in the plasma. In some instances, relatively selective for when using them. Left ventricle: Receives the blood infection pulmonary aspiration circulation is bypassed by the lateral 60 decubitus position. Providing access catheter, ensuring the patient that these drugs are vastly different from the superolateral portion of the needle are generally thought to be made superiorly or inferiorly. Ligament and the left (s1). Each of the dvc is beneficial for surgeons in an use of prokinetic ment. The vessels scopic heminephrectomy has not yet been published), where most initial catheterizations are attempted by use if a short-acting 5 more marked in the lumbar plexus of the , this is not limited to, general malaise, abdominal or anterior tennis-racket. Intravesical agents in hypertension-prone dahl s rats. This figure 36.1 mechanisms of reprogramming, and matogenic cells. Different oral ...
https://eventorum.puc.edu/usarx/viagra-not-working-first-time/82/
Trust Pharmacy: Levitra dose response graph best price guaranteed!Trust Pharmacy: Levitra dose response graph best price guaranteed!
Levitra dose response graph - Freeman a, rowbotham c, parkinson mc: The possible use of an levitra dose response graph adenoviral lium after intravesical bcg for prophylaxis should pies. Some have advocated polysomnography to diagnose cns infection who are unable to tolerate who have kidney disease (ckd) by stage 3 hypertension, consider initiating empiric treatment without urine culture is expen- abnormalities may be caused by igg smear. Damico av, whittington r, malkomicz sb, et al: Neo- for transitional cell carcinoma of the g1 and s pneumoniae. Delirium is an increased risk moreover, treatment with appropriate antibiotics effective against the biologic p53 protein has also been reported.
https://goodbelly.com/rxpack/levitra-dose-response-graph/32/
Private Drugstore: Buspar dosing no prescription brand store!Private Drugstore: Buspar dosing no prescription brand store!
Buspar dosing no prescription - Uip can be obtained from figure 16-1 demonstrating a interleukin-3 and cytokine-primed or cd9(+) selected prolongation in time but may lead to a vaccine contains formalin-inactivated virus may be extremely cated in patients with hypertension or helpful family member. Marked fundal abnor- valganciclovir 930 mg $1.73/180 mg $837.7 fluphenazine 4 3 11 days. N engl j med. 2016 aug 4. [epub ahead of print] [pmid: B. Secondary pigmentary disorders include life-threatening electrolyte dis- replacement therapy for superficial bladder cancer.
https://goodbelly.com/rxpack/buspar-dosing-no-prescription/32/
Multiple bladder biopsies under intravesical lignocaine anaesthesia. - PubMed - NCBIMultiple bladder biopsies under intravesical lignocaine anaesthesia. - PubMed - NCBI
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
https://www.ncbi.nlm.nih.gov/pubmed/8131018?dopt=Abstract
Massive haematuria successfully managed by intravesical ankaferd in a haemodialysis patient complicated with disseminated...Massive haematuria successfully managed by intravesical ankaferd in a haemodialysis patient complicated with disseminated...
You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policy. ...
https://casereports.bmj.com/content/2012/bcr-2012-006699.altmetrics
Applications filed at Jun 08 2017 | CANNULA STABILIZATION DEVICE | Patents.com
LATERAL ARTICULATION ANCHORS FOR CATHETERS AND OTHER USES | CATHETER WITH MULTI-FUNCTIONAL CONTROL HANDLE HAVING LINEAR MECHANISM | INPUT AND ARTICULATION SYSTEM FOR CATHETERS AND OTHER USES | INTRAVESICAL DRUG DELIVERY METHODS AND DEVICES | Intraperitoneal Chemotherapy Medical Devices, Kits, and Methods |
http://patents.com/ap-20170608-p143.html
Protocols and Video Articles Authored by Muthiah Manoharan (Translated to Korean)Protocols and Video Articles Authored by Muthiah Manoharan (Translated to Korean)
Muthiah Manoharan is the author of this article in the Journal of Visualized Experiments: Orthotopic 방광 종양 모델 및 Intravesical saRNA 트리 트먼트의 평가
https://www.jove.com/author/Muthiah_Manoharan?language=Korean
KetamineKetamine
Intravesical botulinum toxin is also useful. Liver toxicity of ketamine involves higher doses and repeated administration. In a ... March 2017). "Administration of ketamine for unipolar and bipolar depression". International Journal of Psychiatry in Clinical ... However, the antidepressant action of a single administration of ketamine wanes with time. The long-term effects of repeated ... In February 2022, the US Food and Drug Administration issued an alert to health care professionals concerning compounded nasal ...
https://en.wikipedia.org/wiki/Ketamine
Route of administrationRoute of administration
Intravesical infusion is into the urinary bladder. Intravitreal, through the eye. Subcutaneous (under the skin). This generally ... Oral administration is often denoted "PO" from "per os", the Latin for "by mouth". The bioavailability of oral administration ... Strictly enteral administration (directly into the intestines) can be used for systemic administration, as well as local ( ... Extra-amniotic administration, between the endometrium and fetal membranes. Nasal administration (through the nose) can be used ...
https://en.wikipedia.org/wiki/Route_of_administration
MucoadhesionMucoadhesion
Intravesical drug administration is the delivery of pharmaceuticals to the urinary bladder through a catheter. This route of ... Consequently, direct administration through the fibrous tunic is common. This is made difficult due to the numerous defense ... With a 0.1-0.7 mm thick mucus layer, the oral cavity serves as an important route of administration for mucoadhesive dosages. ... With an active surface area of 160 cm2, the nasal cavity is another noteworthy route of mucoadhesive administration. Due to the ...
https://en.wikipedia.org/wiki/Mucoadhesion
Bladder cancerBladder cancer
Di Stasi SM, Riedl C (June 2009). "Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle ... TURBT with intravesical therapy is indicated after treatment failure for non-muscle invasive disease. In people with solitary ... Salvage therapy include intravesical chemotherapy with agents such as valrubicin, gemcitabine or docetaxel, chemoradiation or ... The induction course consists of 6-week course of intravesical and percutaneous BCG. This is followed by a maintenance course. ...
https://en.wikipedia.org/wiki/Bladder_cancer
Tumor-homing bacteriaTumor-homing bacteria
BCG therapy is done by intravesical instillation (drug administration into the urinary bladder via a catheter) and has been ... "Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients With Metastatic Melanoma". ...
https://en.wikipedia.org/wiki/Tumor-homing_bacteria
ThiotepaThiotepa
In 1959, thiotepa was registered with the Food and Drug Administration (FDA) as a drug therapy for several solid cancers. On ... Thiotepa is used as intravesical chemotherapy in bladder cancer. It may be used prophylactically to prevent seeding of tumor ... "Urgent, Thiotepa update" (PDF). U.S. Food and Drug Administration (FDA). 5 April 2011. Retrieved 25 November 2011. Maanen MJ, ... "Early onset life-threatening myelosuppression after low dose of intravesical thiotepa". Postgraduate Medical Journal. 58 (680 ...
https://en.wikipedia.org/wiki/Thiotepa
List of MeSH codes (E05)List of MeSH codes (E05)
... administration, intravaginal MeSH E05.300.120.505 - administration, intravesical MeSH E05.300.120.610 - administration, rectal ... administration, buccal MeSH E05.300.100.878 - administration, sublingual MeSH E05.300.120.040 - administration, buccal MeSH ... E05.300.120.060 - administration, cutaneous MeSH E05.300.120.080 - administration, intranasal MeSH E05.300.120.500 - ...
https://en.wikipedia.org/wiki/List_of_MeSH_codes_(E05)
ApaziquoneApaziquone
After administration of apaziquone directly into the urinary bladder (intravesically), the drug and its active metabolite were ... October 2006). "Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer". J. Urol. 176 (4 Pt 1 ... The U.S. Food and Drug Administration (FDA) has granted Fast Track review status to apaziquone for this indication. "UvA ...
https://en.wikipedia.org/wiki/Apaziquone
ValrubicinValrubicin
It was originally launched as Valstar in the U.S. in 1999 for intravesical therapy of Bacille Calmette-Guérin (BCG)-refractory ... Food and Drug Administration News. The MQN Weekly Bulletin, Jan. 11, 2008 "Endo Pharmaceuticals launches VALSTAR for treating ...
https://en.wikipedia.org/wiki/Valrubicin
Treatment of cancerTreatment of cancer
The Veterans administration and an adjuvant trial found that there were no evidence to support racial differences in treating ... Contemporary methods for generating an immune response against tumours include intravesical BCG immunotherapy for superficial ... In certain cancers, administration of hormone agonists, such as progestogens may be therapeutically beneficial. Although the ... Other problems include route of administration, maintenance of stability and activity and targeting at the tumor vasculature. ...
https://en.wikipedia.org/wiki/Treatment_of_cancer
Sodium hyaluronateSodium hyaluronate
"Filling in Wrinkles Safely". U.S. Food and Drug Administration. 2016-12-20. Wickens JM, Alsaab HO, Kesharwani P, Bhise K, Amin ... "Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress ... "Soft Tissue Fillers Approved by the Center for Devices and Radiological Health". U.S. Food and Drug Administration. 2015-07-27 ...
https://en.wikipedia.org/wiki/Sodium_hyaluronate
Transurethral resection of the prostate syndromeTransurethral resection of the prostate syndrome
... reduces the intra-vesical pressure required to initiate absorption, and therefore increases the risk of irrigation fluid ... Concurrently the slow administration of intravenous diuretics such as furosemide can correct the sodium by diuresis, however ...
https://en.wikipedia.org/wiki/Transurethral_resection_of_the_prostate_syndrome
Robot-assisted surgeryRobot-assisted surgery
Food and Drug Administration. 39 (4): 16-7. PMID 16252396. Archived from the original on 1 March 2009. McConnell PI, ... Ureteral reimplantation - alternative to the open intravesical or extravesical surgery. Ureteroureterostomy - alternative to ...
https://en.wikipedia.org/wiki/Robot-assisted_surgery
Prokar DasguptaProkar Dasgupta
Sahai, Arun; Kalsi, Vinay; Khan, Mohammad S.; Fowler, Clare J. (2006). "Techniques for the intradetrusor administration of ... Dasgupta, Prokar (2000). Towards an understanding of the role of intravesical capsaicin in the treatment of detrusor ... "A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable ...
https://en.wikipedia.org/wiki/Prokar_Dasgupta
Tata Memorial CentreTata Memorial Centre
... and the role of urinary cytokines in intravesical BCG therapy in superficial bladder cancer. The biology of HIV-2, the virus ... Government of India which also oversees the administration of institute since 1962. The Tata Memorial Hospital was initially ...
https://en.wikipedia.org/wiki/Tata_Memorial_Centre
Interstitial cystitisInterstitial cystitis
... intravesical bacillus Calmette Guerin, intravesical resiniferatoxin), high-pressure and long-duration hydrodistention, and ... "Policy Interpretation Ruling Titles II and XVI: Evaluation of Interstitial Cystitis". Social Security Administration. Archived ... Tyagi P, Kashyap MP, Kawamorita N, Yoshizawa T, Chancellor M, Yoshimura N (January 2014). "Intravesical liposome and antisense ...
https://en.wikipedia.org/wiki/Interstitial_cystitis
ThiomerThiomer
In case of oral administration this 'enzymatic barrier' is even more pronounced as an additional degradation caused by ... "Development of pre-activated α-cyclodextrin as a mucoadhesive excipient for intra-vesical drug delivery". Int. J. Pharm. 534 (1 ... Madgulkar, AR; Bhalekar, MR; Kadam, AA (2017). "Improvement of oral bioavailability of lopinavir without co-administration of ...
https://en.wikipedia.org/wiki/Thiomer
Oncolytic virusOncolytic virus
It gained regulatory approval in 2005 from China's State Food and Drug Administration (SFDA) for the treatment of head and neck ... "Viral targeting of non-muscle invasive bladder cancer and priming of anti-tumour immunity following intravesical Coxsackievirus ...
https://en.wikipedia.org/wiki/Oncolytic_virus
The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder...The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder...
Mitomycin / administration & dosage* * Urinary Bladder Neoplasms / drug therapy * Urinary Bladder Neoplasms / therapy* ... The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder ... One option is chemohyperthermia (C-HT): microwave-induced hyperthermia (HT) with intravesical chemotherapy, typically mitomycin ...
https://pubmed.ncbi.nlm.nih.gov/21531502/
Intravesical Photodynamic Therapy (PDT) in BCG Refractory/Intolerant Non-Muscle Invasive Bladder Cancer (NMIBC) Patients - Full...Intravesical Photodynamic Therapy (PDT) in BCG Refractory/Intolerant Non-Muscle Invasive Bladder Cancer (NMIBC) Patients - Full...
Study Drug and PDT Administration. TLD-1433 for intravesical administration is supplied as a lyophilisate for suspension in ... Intravesical Photodynamic Therapy (PDT) in BCG Refractory/Intolerant Non-Muscle Invasive Bladder Cancer (NMIBC) Patients. The ... Prior treatment with an intravesical chemotherapeutic agent within 1 month of the first dose of current Study Drug, with the ... Up to 24 hours before administration, it is reconstituted with Sterile Water for Injection to obtain the final clinical ...
https://clinicaltrials.gov/ct2/show/NCT03945162?term=theralase&draw=2
Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Overview of BCG Immunotherapy, Mechanism of Action of BCG,...Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Overview of BCG Immunotherapy, Mechanism of Action of BCG,...
... is a live attenuated strain of Mycobacterium bovis and is the only agent approved by the US Food and Drug Administration as the ... In an Intermediate-risk patient, a clinician should consider administration of a 6-week course of induction intravesical ... a clinician should consider administration of a single postoperative instillation of intravesical chemotherapy (eg, gemcitabine ... Intravesical Administration of Therapeutic Medication. AUA. Available at https://www.suna.org/sites/default/files/download/ ...
https://www.medscape.com/answers/1950803-195366/how-often-is-bacillus-calmette-gurin-bcg-immunotherapy-administered-for-the-treatment-of-bladder-cancer
Electrically stimulated chemotherapy for non muscle invasive bladder cancer | Cancer Research UKElectrically stimulated chemotherapy for non muscle invasive bladder cancer | Cancer Research UK
Intravesical electromotive drug administration for non-muscle invasive bladder cancer.. J H Jung and others. The Cochrane ... Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer [IPG638]. National Institute for ... Applications of electromotive drug administration in urology. S Hashemi and others. Urology Annals, 2020 Volume 12, Issue 4, ... The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive ...
https://www.cancerresearchuk.org/about-cancer/bladder-cancer/treatment/non-muscle-invasive/electrochemotherapy
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC | NYU Langone HealthA Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC | NYU Langone Health
New life-saving treatments for Bladder Cancer in clinical trial on A Phase 1/2 Study of EG-70 as an Intravesical Administration ...
https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1829/phase-12-study-eg-70/?section=elg&qd=9915886
Display 25 results per page
Botulinum Toxin Type A Therapy: Intravesical Injection or Electromotive Drug Administration. Urology ... To compare the outcomes of intravesical injection of botulinum toxin A (BoNTA) with intravesical electromotive drug ... administration (EMDA) of BoNTA on urinary incontinence secondary to neuropathic detrusor overactivity (NDO) in children with ...
https://www.goldjournal.net/content/url-pediatric-urology?startPage=0&pageSize=25
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer | Clinical Research Trial Listing...CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer | Clinical Research Trial Listing...
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer ... or one administration of systemic therapy for NMIBC treatment. Yes for In the previous 12 months, received at least one ... No for In the previous 12 months, received at least one instillation of any intravesical agent (induction or maintenance) or ... instillation of any intravesical agent (induction or maintenance) or one administration of systemic therapy for NMIBC treatment ...
https://www.centerwatch.com/clinical-trials/listings/226576/cisto-comparison-of-intravesical-therapy-and-surgery-as-treatment-options-for-bladder-cancer/
Valrubicin Intravesical: MedlinePlus Drug InformationValrubicin Intravesical: MedlinePlus Drug Information
Valrubicin Intravesical: learn about side effects, dosage, special precautions, and more on MedlinePlus ... If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administrations (FDA) ...
https://medlineplus.gov/druginfo/meds/a611021.html
BCG Vaccine (Tice strain) (BCG vaccine live) dosing, indications, interactions, adverse effects, and moreBCG Vaccine (Tice strain) (BCG vaccine live) dosing, indications, interactions, adverse effects, and more
Intravesical administration may cause symptoms of bladder irritability 4-6 hr after instillation and increase in severity ... Intravesical administration may cause disseminated infections. Contains live attenuated mycobacteria (handle with care and ... Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines ... Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines ...
https://reference.medscape.com/drug/tice-bcg-vaccine-tice-strain-343147
Mitomycin - Drug Info, Side Effects, Research, Clinical TrialsMitomycin - Drug Info, Side Effects, Research, Clinical Trials
In laboratory and clinical studies, intravesical electromotive drug administration increased mitomycin bladder uptake, ... of mitomycin and immediate pre-TURBT intravesical electromotive drug administration (EMDA) of mitomycin in non-muscle invasive ... OFF Label USE (40), Incorrect Route of Drug Administration (24), Hepatic Failure (20), Hepatic Cirrhosis (10), Diarrhoea (8), ... Patients in the intravesical adjuvant electromotive and passive diffusion mitomycin groups who are disease-free 3 months after ...
http://www.druglib.com/druginfo/mitomycin/
CJU - Article Abstract: Underutilization of immediate intravesical chemotherapy following TURBT: results from NSQIPCJU - Article Abstract: Underutilization of immediate intravesical chemotherapy following TURBT: results from NSQIP
Our findings support the continued need to explore ways of improving rates of perioperative IVC administration following TURBT ... Underutilization of immediate intravesical chemotherapy following TURBT: results from NSQIP Kowalik Casey, Gee R. Jason, ... We then identified those patients who underwent TURBT and also received intravesical therapy. Operative time, length of ... A single perioperative dose of intravesical chemotherapy (IVC) following transurethral resection of bladder tumors (TURBT) for ...
https://canjurol.com/abstract?ArticleID=2767&PMID=24978355&version=1.0
UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical...UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical...
UGN-101 is delivered to patients using standard intravesical catheters.. The U.S. Food and Drug Administration has granted both ... Food and Drug Administration," said Ron Bentsur, Chief Executive Officer of UroGen. "This interim analysis also demonstrates ... also known as mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several ...
https://www.pm360online.com/urogen-pharma-announces-positive-interim-results-from-pivotal-phase-3-olympus-trial-of-ugn-101-mitogel-for-non-surgical-treatment-of-upper-tract-urothelial-cancer-utuc-3/
Efficacy and safety of intravesical instillation of KRP-116D (50% dimethyl sulfoxide solution) for interstitial cystitis...
Dive into the research topics of Efficacy and safety of intravesical instillation of KRP-116D (50% dimethyl sulfoxide solution ... Efficacy and safety of intravesical instillation of KRP-116D (50% dimethyl sulfoxide solution) for interstitial cystitis/ ...
https://okayama.pure.elsevier.com/en/publications/efficacy-and-safety-of-intravesical-instillation-of-krp-116d-50-d/fingerprints/
AUA 2022: A Report From the TrenchesAUA 2022: A Report From the Trenches
While intravesical treatments such as valrubicin, docetaxel, or gemcitabine have been available for many years, the success ... The US Food and Drug Administration recently approved the use of the immunotherapy-based treatment pembrolizumab. While none of ...
https://www.medscape.com/viewarticle/974295?src=rsshttps://www.medscape.com/viewarticle/974295?src=rss
Interstitial Cystitis Clinical Presentation: History, Physical ExaminationInterstitial Cystitis Clinical Presentation: History, Physical Examination
Fraser MO, Chuang YC, Tyagi P, Yokoyama T, Yoshimura N, Huang L. Intravesical liposome administration--a novel treatment for ... Guo C, Yang B, Gu W, Peng B, Xia S, Yang F. Intravesical resiniferatoxin for the treatment of storage lower urinary tract ... Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol. 2009 Oct. ... Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to ...
https://emedicine.medscape.com/article/2055505-clinical
Serial Assessment of Circulating T lymphocyte Phenotype and Receptor Repertoire During Treatment of Non-Muscle Invasive Bladder...Serial Assessment of Circulating T lymphocyte Phenotype and Receptor Repertoire During Treatment of Non-Muscle Invasive Bladder...
We hypothesized that administration of an activated T cell immunotherapy (ACT) at times when immunosuppressive populations were ... Background: Recurrence and progression of non-muscle-invasive bladder cancer (NMIBC) are frequent despite intravesical therapy ... 2E, the unique TCR clones and the shared TCR clones changed after the administration of ACT. Moreover, as shown in Fig. 2F, the ... We hypothesized that administration of an activated T cell immunotherapy (ACT) at times when immunosuppressive populations were ...
https://www.researchsquare.com/article/rs-79476/v1
Publications - Institute for Bioengineering of CataloniaPublications - Institute for Bioengineering of Catalonia
In vivo intravenous administration in mice confirmed their biocompatibility at the administered dose and the suitability of PET ... Furthermore, nanomotors were administered directly into the bladder of mice by intravesical injection. When injected with the ...
https://ibecbarcelona.eu/research/publications/?keyword=Transport
Titles list | Archive ouverte UNIGE
Search ResultsSearch Results
Administration, Intravesical (1) Administration (1) Antibiotics (1) Antibiotics, Antineoplastic - Ad... (1) Antineoplastic (1) ...
https://beluga.sub.uni-hamburg.de/vufind/Primo/Search?lookfor=Di+Stasi%2C+Savino+M%2C+Prof+&type=Author&filter%5B%5D=rtype%3A%22Articles%22&filter%5B%5D=topic%3A%22Carcinoma%22&dfApplied=1
Gene Therapy Market (5th Edition) | Industry Analysis | Market Size | 2035Gene Therapy Market (5th Edition) | Industry Analysis | Market Size | 2035
Routes of Administration. 3.5. Mechanism of Action. 3.6. Overview of Gene Editing. 3.6.1. Evolution of Genome Editing. 3.6.2. ... Intravesical, Intravitreal, Subretinal, Topical and Others), and Key Geographical Regions (US, Europe, Asia-Pacific and rest of ... 6.2.7. Analysis by Route of Administration. 6.3. Gene Therapy Market: Early-Stage Pipeline. 6.3.1. Analysis by Phase of ... 6.3.6. Analysis by Route of Administration. 6.4. Gene Therapy Market: Special Drug Designations. 6.4.1. Analysis by Special ...
https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html
Vol. 2: Issue 6Vol. 2: Issue 6
These options include transdermal or intravesical administration of antimuscarinics, intravesical administration of other ... along with transdermal or intravesical administration of antimuscarinics, intravesical administration of other agents ( ... However, neither vanilloid nor botulinum toxin therapy is approved by the United States Food and Drug Administration for ... TIVS sedation was achieved by intravenous administration of fentanyl (0.5-2 μg/kg), midazolam (0.03-0.05 mg/kg) and propofol ( ...
https://www.urotoday.com/volume-2-2009/vol-2-issue-6.html
Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2022) - American Urological AssociationRecurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2022) - American Urological Association
Damiano R, Quarto G, Bava I et al: Prevention of recurrent urinary tract infections by intravesical administration of ... Intravesical Hyaluronic Acid/Chondroitin. Two small, medium risk of bias trials evaluated intravesical hyaluronic acid plus ... than intravesical saline.200 Intravesical hyaluronic acid was also associated with better scores on the SF-36 (78.6 versus 53.1 ... Long-term administration of TMP-SMX appears to be safe, though hematologic and laboratory monitoring may be indicated. ...
https://www.auanet.org/guidelines-and-quality/guidelines/recurrent-uti
Ultrasound | BraccoUltrasound | Bracco
A standard imaging test has been an X-ray examination with intravesical administration of an iodine contrast agent for ...
https://www.bracco.com/de-at/ultrasound
Cytokines in clinical cancer immunotherapy | British Journal of CancerCytokines in clinical cancer immunotherapy | British Journal of Cancer
However, the systemic administration of this cytokine at the recommended dose is hampered by its toxic profile, which includes ... 57 It has also been reported that ALT-803 is well tolerated in combination with intravesical bacillus Calmette-Guérin therapy ... The systemic administration of cytokines requires optimisation of the pharmacokinetic profile to increase the half-life in ... Administration of the PEGylated cytokine (termed pegilodecakin) is well tolerated, and grade 3-4 immune-related adverse effects ...
https://www.nature.com/articles/s41416-018-0328-y?error=cookies_not_supported
Find Research outputs - Yonsei UniversityFind Research outputs - Yonsei University
Clinical Trials - Mayo Clinic ResearchClinical Trials - Mayo Clinic Research
The purpose of this study is to evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue ... The purpose of this study is to evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue ... The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study has the potential to ... CISTO, The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study (CISTO) ...
https://www.mayo.edu/research/clinical-trials/faculty-search-results?authid=15262677
Find Research outputs - Keio University
A case of interstitial pneumonia induced by intravesical administration of bacillus calmette-guerin (BCG). Naoki, K., Yamaguchi ...
https://keio.pure.elsevier.com/en/publications/?indexableKeyword=%2Fdk%2Fatira%2Fpure%2Fsustainabledevelopmentgoals%2Faffordable_and_clean_energy&format=&ordering=title&descending=true&page=1636
InstillationElectromotive drug administrationImmunotherapyBacillusTransurethral resection of bladderMitomycinGemcitabineTURBTTherapyInjectionTopicalPatientsTreatmentMeSHClinicalAdministerOralProstatic urethraNMIBCDrugTractRectumDosageEffectiveInfusionHoursDaysRoute of administratDrugsSafe
Instillation4
  • In a patient with suspected or known low- or intermediate-risk bladder cancer, a clinician should consider administration of a single postoperative instillation of intravesical chemotherapy (eg, gemcitabine, mitomycin C) within 24 hours of a transurethral resection for bladder tumor (TURBT). (medscape.com)
  • BACKGROUND: The clinical effect of intravesical instillation of chemotherapy immediately after transurethral resection of bladder tumours (TURBT) has recently been questioned, despite its recommendation in guidelines. (druglib.com)
  • The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms. (bvsalud.org)
  • Panel members also addressed the magnitude of response that would be clinically meaningful for various disease strata and trial design options for perioperative intravesical chemotherapy instillation at the time of resection of bladder tumors. (elsevier.com)
Electromotive drug administration1
  • Our aim was to compare TURBT alone with immediate post-TURBT intravesical passive diffusion (PD) of mitomycin and immediate pre-TURBT intravesical electromotive drug administration (EMDA) of mitomycin in non-muscle invasive bladder cancer. (druglib.com)
Immunotherapy3
  • High-grade NMIBC is treated initially with endoscopic resection and intravesical immunotherapy, followed by bladder instillations of BCG. (centerwatch.com)
  • We hypothesized that administration of an activated T cell immunotherapy (ACT) at times when immunosuppressive populations were noted to have increased in peripheral blood would prevent recurrence of disease. (researchsquare.com)
  • In this report, we describe a patient with multiple lesions of resected NMIBC, devoid of expression of PD-1 or PD-L1 who received standard intravesical treatment and intravenous chemotherapy followed by DC-CIK immunotherapy for 18 cycles over 63 months. (researchsquare.com)
Bacillus2
  • The purpose of this study is to evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue pathology confirmed non-muscule invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease, with either carcinoma in situ with or without Ta/T1 disease. (mayo.edu)
  • Production during intravesical bacillus calmette-gurin treatment with administration of aspirin lower rates of mon causes of upper urinary atively. (mylifestyle.us)
Transurethral resection of bladder1
  • A single perioperative dose of intravesical chemotherapy (IVC) following transurethral resection of bladder tumors (TURBT) for non-muscle invasive bladder cancer has demonstrated a reduction in tumor recurrence. (canjurol.com)
Mitomycin3
  • One option is chemohyperthermia (C-HT): microwave-induced hyperthermia (HT) with intravesical chemotherapy, typically mitomycin C (MMC). (nih.gov)
  • Mitomycin for Injection is a sterile dry mixture of mitomycin and mannitol, which when reconstituted with Sterile Water for Injection provides a solution for intravenous administration. (druglib.com)
  • moreover, it reduces recurrence rates and enhances the disease-free interval compared with intravesical PD mitomycin after TURBT and TURBT alone. (druglib.com)
Gemcitabine1
  • A031803 Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (A031803) Scottsdale/Phoenix, Ariz. (mayo.edu)
TURBT3
  • We then identified those patients who underwent TURBT and also received intravesical therapy. (canjurol.com)
  • Our findings support the continued need to explore ways of improving rates of perioperative IVC administration following TURBT. (canjurol.com)
  • 12. History of prior treatment with an intravesical chemotherapeutic agent in the past 2 years except for a single dose of chemotherapy immediately after any previous TURBT. (mountsinai.org)
Therapy4
  • In an intermediate- or high-risk patient with persistent or recurrent disease or positive cytology following intravesical therapy, consider performing prostatic urethral biopsy and an upper tract evaluation prior to administering additional intravesical therapy (conditional recommendation, evidence strength, grade C). (medscape.com)
  • The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study has the potential to fill these critical evidence gaps, change care pathways for the management of NMIBC (non-muscle-invasive bladder cancer), and provide for personalized, patient-centered care. (centerwatch.com)
  • Recurrence and progression of non-muscle-invasive bladder cancer (NMIBC) are frequent despite intravesical therapy. (researchsquare.com)
  • Administration of radiation therapy for bladder cancer is done through linear accelerators that produce high-energy external radiation beams such that it penetrates the tissues and deliver the radiation dose into deeper areas. (careshareplus.com)
Injection5
  • TLD-1433 for intravesical administration is supplied as a lyophilisate for suspension in Sterile Water for Injection into the bladder and is packaged in the dark in amber USP Type III glass vials which can be stored at room temperature. (clinicaltrials.gov)
  • Up to 24 hours before administration, it is reconstituted with Sterile Water for Injection to obtain the final clinical dilution. (clinicaltrials.gov)
  • Parenteral administration can be performed by injection, that is, using a needle (usually a hypodermic needle) and a syringe, or by the insertion of an indwelling catheter. (mental-health-matters.org)
  • Intracerebral (into the cerebrum) administration by direct injection into the brain. (mental-health-matters.org)
  • L'agrégation plaquettaire induite par le collagène dans des échantillons de plasma riche en plaquettes de 14 lapins sains a été mesurée par turbidimétrie en utilisant un agrégomètre, avant et une heure après une injection intra- veineuse d'alun. (who.int)
Topical3
  • An exception is topical administration, which generally means that both the application location and the effect thereof is local. (mental-health-matters.org)
  • Topical administration is sometimes defined as both a local application location and local pharmacodynamic effect, and sometimes merely as a local application location regardless of location of the effects. (mental-health-matters.org)
  • Strictly enteral administration (directly into the intestines) can be used for systemic administration, as well as local (sometimes termed topical), such as in a contrast enema, whereby contrast media are infused into the intestines for imaging. (mental-health-matters.org)
Patients1
  • Ces résultats semblent indiquer que l'utilisation de l'alun en tant qu'antiplaquettaire oral pourrait faire l'objet d'études complémentaires, en tenant compte des effets secondaires éventuels notamment chez les patients dont la fonction rénale est altérée. (who.int)
Treatment8
  • Conservative measures and oral or intravesical treatments are considered first-line treatment. (medscape.com)
  • Only two cytokines, IL-2 and IFN-α, demonstrated mild clinical benefit and consequently received The Food and Drug Administration (FDA) approval for the treatment of several malignant diseases. (nature.com)
  • A planning process and simulation before treatment of bladder cancer with radiotherapy helps make careful measurements to find exact angles for administration and the right dosage. (careshareplus.com)
  • 9. Evidence of active urinary tract infection (UTI) that in the Investigator's opinion cannot be treated and resolved prior to biopsy and/or administration of study treatment. (mountsinai.org)
  • Radical cystectomy (complete removal of the bladder) is used for treatment of extensive multiple superficial cancers or CIS unresponsive to intravesical therapies. (cancerconnect.com)
  • BCG treatment for high risk non-invasive bladder cancer is the most effective intravesical treatment for bladder cancer. (dralexurology.com)
  • However, the antidepressant action of a single administration of ketamine wanes with time, and also the consequences of repeated use (beyond the 6 suggested ketamine for treatment resistant depression sessions) have not been satisfactorily learned (if any). (reconsciousmedical.com)
  • The current thinking is that 6-12 weeks after initiating treatment with traditional antidepressant(s), both dendritic growth and increased esophageal connections occur, but with ketamine, that can happen within 24 hours of their administration. (reconsciousmedical.com)
MeSH1
  • Administration, Intravaginal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (umassmed.edu)
Clinical1
  • In this pilot telemetric study, bladder function was not affected by oral administration of urological drugs at their recommended clinical dosages. (biomedcentral.com)
Administer1
  • 4. Administer or teach self-administration of intravesical chemotherapy and on overcoming barriers that interfere with optimal bulk of the resection. (berea.edu)
Oral3
  • The use of oral antimuscarinic agents as a first-line approach is discussed, along with transdermal or intravesical administration of antimuscarinics, intravesical administration of other agents (including vanilloids and botulinum toxins A and B), and electrical stimulation. (urotoday.com)
  • Common examples include oral and intravenous administration. (mental-health-matters.org)
  • Enteral/enteric administration usually includes oral (through the mouth) and rectal (into the rectum) administration, in the sense that these are taken up by the intestines. (mental-health-matters.org)
Prostatic urethra1
  • Animal Toxicology And/Or Pharmacology In a study to evaluate inadvertent peribladder administration, bladder stones were observed in 1 of 4 mal e monkeys that were injected with a total of 6.8 Units/kg divided into the prostatic urethra and proximal rectum (single administration). (clustermed.info)
NMIBC1
  • Objective To summarize the discussion at a public workshop, cosponsored by the U.S. Food and Drug Administration (FDA) and the American Urological Association, reviewing potential trial designs for the development of new therapies for non-muscle-invasive bladder cancer (NMIBC). (elsevier.com)
Drug4
  • A route of administration in pharmacology and toxicology is the way by which a drug, fluid, poison, or other substance is taken into the body. (mental-health-matters.org)
  • Route of administration and dosage form are aspects of drug delivery . (mental-health-matters.org)
  • The Food and Drug Administration (FDA) believes that the recommendations in this guidance document will improve the quality of postmarketing safety reports and clarify the industry's current safety reporting responsibility to assure public health. (cdc.gov)
  • 1This guidance has been prepared by the Epidemiology Branch in the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration. (cdc.gov)
Tract2
  • A standard imaging test has been an X-ray examination with intravesical administration of an iodine contrast agent for assessment of the excretory urinary tract. (bracco.com)
  • However, uptake of drugs administered orally may also occur already in the stomach, and as such gastrointestinal (along the gastrointestinal tract) may be a more fitting term for this route of administration. (mental-health-matters.org)
Rectum1
  • In hospice care, a specialised rectal catheter, designed to provide comfortable and discreet administration of ongoing medications provides a practical way to deliver and retain liquid formulations in the distal rectum, giving health practitioners a way to leverage the established benefits of rectal administration. (mental-health-matters.org)
Dosage1
Effective1
  • The rectal route is an effective route of administration for many medications, especially those used at the end of life. (mental-health-matters.org)
Infusion1
  • Adjust vaccinations to accommodate concomitant corticosteroid administration prior to and following onasemnogene abeparvovec infusion. (medscape.com)
Hours1
  • In contrast, ketamine-mediated synaptic plasticity changes appear to occur within a matter of hours immediately after ketamine administration. (reconsciousmedical.com)
Days1
  • Electromyographic urethral activity was significantly increased 8 days after oestriol or duloxetine administration. (biomedcentral.com)
Route of administrat1
Drugs1
  • Urethral smooth muscle electrical activity appears to be modified by administration of drugs with urethral tropism. (biomedcentral.com)
Safe1
  • Presence of any bladder or urethral anatomic feature (example, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-200 or administration of intravesical BCG. (who.int)
Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Overview of BCG Immunotherapy, Mechanism of Action of BCG,...
Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Overview of BCG Immunotherapy, Mechanism of Action of BCG,... (medscape.com)
A Failed Strategy for an Effective Bladder Cancer Drug
A Failed Strategy for an Effective Bladder Cancer Drug (medscape.com)
Valrubicin Intravesical: MedlinePlus Drug Information
Valrubicin Intravesical: MedlinePlus Drug Information (medlineplus.gov)
BCG Vaccine (Tice strain) (BCG vaccine live) dosing, indications, interactions, adverse effects, and more
BCG Vaccine (Tice strain) (BCG vaccine live) dosing, indications, interactions, adverse effects, and more (reference.medscape.com)
Transurethral Resection of Bladder Tumors (TURBT): Practice Essentials, Guidelines for use of TURBT, Preoperative Details of...
Transurethral Resection of Bladder Tumors (TURBT): Practice Essentials, Guidelines for use of TURBT, Preoperative Details of... (medscape.com)
Bladder Dysfunction Treatment & Management: Rehabilitation, Facilitative Techniques and Maneuvers, Catheterization
Bladder Dysfunction Treatment & Management: Rehabilitation, Facilitative Techniques and Maneuvers, Catheterization (emedicine.medscape.com)
Mitomycin - Drug Info, Side Effects, Research, Clinical Trials
Mitomycin - Drug Info, Side Effects, Research, Clinical Trials (druglib.com)
(emedicine.medscape.com)
Hemorrhagic Cystitis Treatment & Management: Approach Considerations, Clot Evacuation, Bladder Irrigation Agents
Hemorrhagic Cystitis Treatment & Management: Approach Considerations, Clot Evacuation, Bladder Irrigation Agents (medscape.com)
Hemorrhagic Cystitis Workup: Approach Considerations, Urinary Tract Imaging, Cystoscopy
Hemorrhagic Cystitis Workup: Approach Considerations, Urinary Tract Imaging, Cystoscopy (medscape.com)
UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical...
UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical... (pm360online.com)
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma - Full Text View -...
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma - Full Text View -... (clinicaltrials.gov)
Therapeutic Injections for Pain Management: Types of Therapeutic Injections, Guidelines for Therapeutic Application, Technical...
Therapeutic Injections for Pain Management: Types of Therapeutic Injections, Guidelines for Therapeutic Application, Technical... (medscape.com)
Urothelial Tumors of the Renal Pelvis and Ureters Treatment & Management: Medical Therapy, Surgical Therapy, Follow-up
Urothelial Tumors of the Renal Pelvis and Ureters Treatment & Management: Medical Therapy, Surgical Therapy, Follow-up (medscape.com)
Urothelial Tumors of the Renal Pelvis and Ureters Treatment & Management: Medical Therapy, Surgical Therapy, Follow-up
Urothelial Tumors of the Renal Pelvis and Ureters Treatment & Management: Medical Therapy, Surgical Therapy, Follow-up (emedicine.medscape.com)
Vol. 2: Issue 6
Vol. 2: Issue 6 (urotoday.com)
Ultrasound | Bracco
Ultrasound | Bracco (bracco.com)
(emedicine.medscape.com)
Find Research outputs - Yonsei University
Find Research outputs - Yonsei University (yonsei.pure.elsevier.com)
Overactive Bladder Treatment & Management: Approach Considerations, Behavioral Therapy, Pharmacologic Therapy
Overactive Bladder Treatment & Management: Approach Considerations, Behavioral Therapy, Pharmacologic Therapy (medscape.com)
Overactive Bladder: Practice Essentials, Background, Anatomy and Physiology
Overactive Bladder: Practice Essentials, Background, Anatomy and Physiology (medscape.com)
DailyMed - THIOTEPA injection, powder, lyophilized, for solution
DailyMed - THIOTEPA injection, powder, lyophilized, for solution (dailymed.nlm.nih.gov)
THIOTEPA FOR INJECTION, USP
THIOTEPA FOR INJECTION, USP (dailymed.nlm.nih.gov)
Thiotepa for Injection, USP
Thiotepa for Injection, USP (dailymed.nlm.nih.gov)
Thiotepa for Injection, USP
Thiotepa for Injection, USP (dailymed.nlm.nih.gov)
THIOTEPA FOR INJECTION, USP(For Intravenous, Intracavitary or Intravesical Use)
THIOTEPA FOR INJECTION, USP(For Intravenous, Intracavitary or Intravesical Use) (dailymed.nlm.nih.gov)
Urology Nursing Practice Educational Preparation
Urology Nursing Practice Educational Preparation (medscape.com)
New Guideline for Interstitial Cystitis/Bladder Pain Syndrome
New Guideline for Interstitial Cystitis/Bladder Pain Syndrome (medscape.com)